

Review

# Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?

Lisa Sequeira, Sofia Benfeito , Carlos Fernandes, Inês Lima, Joana Peixoto , Catarina Alves ,  
Cláudia Sofia Machado, Alexandra Gaspar, Fernanda Borges \* and Daniel Chavarria \*

CIQUP-IMS—Centro de Investigação em Química da Universidade do Porto, Institute of Molecular Sciences, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, R. Campo Alegre s/n, 4169-007 Porto, Portugal

\* Correspondence: fborges@fc.up.pt (F.B.); daniel.chavarria@fc.up.pt (D.C.)

**Abstract:** Neurodegenerative diseases (NDs) are a set of progressive, chronic, and incurable diseases characterized by the gradual loss of neurons, culminating in the decline of cognitive and/or motor functions. Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common NDs and represent an enormous burden both in terms of human suffering and economic cost. The available therapies for AD and PD only provide symptomatic and palliative relief for a limited period and are unable to modify the diseases' progression. Over the last decades, research efforts have been focused on developing new pharmacological treatments for these NDs. However, to date, no breakthrough treatment has been discovered. Hence, the development of disease-modifying drugs able to halt or reverse the progression of NDs remains an unmet clinical need. This review summarizes the major hallmarks of AD and PD and the drugs available for pharmacological treatment. It also sheds light on potential directions that can be pursued to develop new, disease-modifying drugs to treat AD and PD, describing as representative examples some advances in the development of drug candidates targeting oxidative stress and adenosine A2A receptors.

**Keywords:** neurodegenerative diseases; Parkinson's disease; Alzheimer's disease; drug discovery; disease-modifying drugs



**Citation:** Sequeira, L.; Benfeito, S.; Fernandes, C.; Lima, I.; Peixoto, J.; Alves, C.; Machado, C.S.; Gaspar, A.; Borges, F.; Chavarria, D. Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now? *Pharmaceutics* **2024**, *16*, 708. <https://doi.org/10.3390/pharmaceutics16060708>

Academic Editor: Xiaoyong Wang

Received: 4 April 2024

Revised: 15 May 2024

Accepted: 22 May 2024

Published: 24 May 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


## 1. Introduction

Neurodegenerative diseases (NDs) are a set of progressive, chronic, and incurable neurological disorders characterized by the loss of neurons and synaptic connections, which irreversibly produce a series of events commonly related to motor disability, cognitive impairment, and dementia [1]. They represent an enormous disease burden, both in terms of human suffering and economic costs [2], being the foremost contributors to incapacity and dependence due to their debilitating nature [3]. The most common NDs include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and Amyotrophic Lateral Sclerosis (ALS).

The etiology of NDs is not completely understood and the onset of neurodegeneration may precede the clinical symptoms by many years. However, it is generally accepted that the pathogenesis of NDs is multifactorial, involving a complex combination of genetic, environmental, and endogenous factors acting cooperatively or independently [4,5]. Although each disease presents its particular molecular mechanisms and clinical manifestations (Figure 1), NDs share common pathogenic events [6].

Despite the intensive research performed so far, to date, no breakthrough treatment has been discovered. The available therapies for NDs only provide symptomatic and palliative relief for a limited period [7] and are unable to modify the disease progression [8,9]. Therefore, the development of disease-modifying drugs able to prevent, halt or reverse the progression of NDs remains an unmet clinical need. In this review, we summarize the major hallmarks of AD and PD, the drugs available for pharmacological treatment,

and future directions for the development of new and disease-modifying drugs to treat these NDs.



**Figure 1.** Primary brain regions affected in the most common neurodegenerative diseases. Adapted from [6].

## 2. Alzheimer's and Parkinson's Diseases: The Epidemiologic Forecast

The average human lifespan of the worldwide population has been rising in recent decades [10]. Several factors seem to contribute to this success, namely the cumulative progress in sanitation and medical care, rising living standards, and the decline in child mortality [10,11]. Although the increased life expectancy must be celebrated, a proportional rise in the frequency and prevalence of NDs is expected [10,12]. Therefore, the rise of elderly populations has been soaring with the increased incidence of age-related degenerative diseases, reaching epidemic proportions in high-income countries [13]. Several genetic risk factors, lifestyles, and environmental exposure to a diversity of pollutants are implicated in the neurodegeneration process [14]. In 2020, the worldwide population with age higher than 65 years was estimated to be 727 million, a 195 million increase since 2010. Over the next three decades, the number of worldwide elderly is projected to more than double, reaching over 1.5 billion in 2050. By mid-century, one in six people globally will be aged 65 years or older [15]. Although the increase in longevity represents a progress *per se*, it can become a social, economic, and medical burden when it is not associated with the maintenance of the quality of life. The World Health Organization indicated that central nervous system (CNS) diseases are the major medical challenge of the 21st Century. Among them, NDs, namely AD and PD, are the most prevalent CNS disorders [16].

The World Health Organization recognized AD as the most common form of dementia in the elderly, accounting for 50–56%, and a major cause of death, being considered one of the greatest global public health challenges [17,18]. Currently, the number of people aged 65 and older affected by AD dementia is more than 55 million worldwide and it is expected that this number will rapidly increase to 132 million by 2050 [19,20].

The overall number of people diagnosed with PD has also been growing progressively at a global level. In 2019, approximately 8.5 million individuals received a PD diagnosis. Estimates suggest that, in 2019, PD resulted in 5.8 million disability-adjusted life years, an increase of 81% since 2000, and caused 329,000 deaths, an increase of over 100% since 2000. This estimation is expected to increase to 12 million people in 2050 [21,22].

## 3. Major Hallmarks of Alzheimer's and Parkinson's Diseases

### 3.1. Alzheimer's Disease

Alzheimer's disease was first diagnosed in 1906 by Dr. Alois Alzheimer, when he noticed changes in the brain tissue of a woman who had died of an unusual mental illness [23].

AD is an irreversible, complex, and progressive ND that results in cognitive impairment and memory injury. Despite its prevalence among the elderly, AD dementia is distinct from a normal aging process [24]. The progression of AD can be divided into three stages. The first is often mistakenly attributed to age-related upsets or manifestations of stress [25]. In this stage, the patient has memory lapses such as forgetting familiar words or the location of everyday objects, which denotes its lack of ability to produce new memories and


skills [26,27]. The second stage of AD is typically the longest one and can last for many years. Herein, the progressive deterioration of neurons can lead to problems with speech and severe difficulties in reading and writing. During this phase, memory problems worsen, and the patient may fail to recognize close relatives [28]. In the most advanced phase, AD patients show loss of cognitive and motor functions, confusion, and disorientation, with most patients having mobility problems, hallucinations, and delirium, leading to absolute dependence on 24 h supervision, hospital care, and unavoidable death [29,30].

Although the specific cause of AD is still unknown, it is well recognized that a multiplicity of pathological stimuli can play a key role, which causes an increased risk of disease development [31,32]. Age and family history of the disease are considered the strongest risk factors for familial and sporadic AD [33]. The presence of the  $\epsilon 4$  allele of the apolipoprotein E4 (ApoE4) genotype, found on chromosome 19, appears to be a primarily risk factor for patients with sporadic AD [34–36]. In addition, genetic mutations in APP on chromosome 21, presenilin-1 (PSEN-1) on chromosome 14, and presenilin-2 (PSEN-2) on chromosome 1 can also cause familial AD [37,38]. Other putative risk factors include head trauma, depression, diabetes mellitus, hypothyroidism, and a series of vascular factors [39,40].

A conclusive diagnosis of AD requires a detailed post-mortem microscopic examination of the brain [37]. However, AD can be currently diagnosed with more than 95% accuracy in living patients by carefully analyzing the patients' family history, assessing cognitive function with neuropsychological tests, and evaluating AD biomarkers, namely with high-tech neuroimaging data or cerebrospinal fluid analysis [41,42].

The progressive cognitive impairment observed in AD patients can be associated with the significant reduction of brain size [43]. The brain atrophy arises from the loss of synapses and from the selective neuronal death in the hippocampus and in the cerebral cortex [43–46]. The most prominent losses are observed in neurons with long projections, such as cholinergic neurons in the basal forebrain (Figure 2A) [47]. These neurons innervate the hippocampus, thalamus, amygdala, and neocortex, and play key roles in attention, cognitive flexibility, and learning [48]. Although the neurons that degenerate in AD are mostly cholinergic [49], glutamatergic neurons are also affected [50].

AD is characterized by extensive atrophy of the brain caused by two main neuropathologic changes—the formation of amyloid plaques (also called senile plaques) and the appearance of neurofibrillary tangles (NFTs)—that lead to neuronal loss and synaptic changes in brain-specific areas essential for cognitive and memory functions (Figure 2B) [51].



**Figure 2.** Major hallmarks of AD. (A) Degeneration of cholinergic neurons in the basal forebrain. (B) Formation of senile plaques and neurofibrillary tangles. Adapted from [52].

The amyloid plaques result from the abnormal extracellular accumulation and deposition of insoluble aggregates of fibrillar  $\beta$ -amyloid ( $A\beta$ ) [53]. Sequential cleavage of the amyloid precursor protein (APP) in the cell membrane by the enzymes- $\beta$  and  $\gamma$ -secretases gives rise to the family of  $A\beta$  peptides (most commonly, 40–42 amino acids in length) [54,55]. Although the formation of  $A\beta$  is believed to be a physiological process in normal aging [56],  $A\beta$ 1-42 isoform was identified as a major contributor to the disease process [57,58].

Intracellular NFTs are formed by aggregated misfolded tau protein (tau-P), the major microtubule-associated protein predominantly found in the axons of mature neurons [59]. In AD, tau hyperphosphorylation induces a loss of function that hampers its ability to bind to microtubules, leading to microtubule depolymerization that compromises the axonal trafficking and the dendrite structure [60]. When tangle-bearing neurons die, NFTs become extraneuronal and activate a series of neurotoxic processes that can cause synaptic dysfunction and neuronal death [61]. Overall, AD brains show a decline in neuronal mass in regions related to cognition and memory, which leads to a depletion of cholinergic neurons and acetylcholine (ACh), resulting in synaptic dysfunction [47,62].

Other pathological features also play a crucial role in the progress of AD, including cholinergic deficit, enhanced brain oxidative stress, the overproduction of free radical, mitochondrial dysfunction, and the disruption of metal homeostasis [63]. The downstream consequences of neuropathological processes contribute to neurodegeneration, with extensive neuronal loss, synaptic changes, and brain neurotoxic events leading to macroscopic atrophy [18,64].

### 3.2. Parkinson's Disease


Initially described by the English surgeon James Parkinson in 1817, Parkinson's disease is the second most prevalent ND and the most common movement disorder [65].

Clinical manifestations of PD include four cardinal motor symptoms: bradykinesia, resting tremor, rigidity, and postural instability [66,67]. Patients with PD may also experience numerous non-motor symptoms, such as autonomic deficiency, cognitive impairment, neuropsychiatric problems (mood, cognition, behavior, or thought alterations), and both sensory (especially altered sense of smell) and sleep disorders [7,67–69]. Non-motor symptoms are common in the PD early stages (pre-motor/prodromal phase) and frequently precede the onset of motor symptoms [68,69]. Motor dysfunction worsens with the disease progression and is managed with symptomatic treatments [69]. However, long-term therapy is associated with the gradual loss of efficacy and the emergence of adverse effects such as motor fluctuations, dyskinesia, and psychosis [69,70]. Late-stage PD is characterized by treatment-resistant motor and non-motor symptoms that substantially contribute to the patient's disability [69]. The median age of the onset of PD is 60 years, and the mean duration from diagnosis to death is 15 years [67].

Parkinson's disease is mostly sporadic, resulting from a complex interplay between genetic susceptibility and environmental factors [66]. However, approximately 5–10% of PD cases are caused by familial genetic mutations [71,72] that usually result in early onset PD [73]. Mutations in *SNCA*, *LRRK2* and *VPS35* genes were associated with autosomal dominant PD, while mutations in *PINK1*, *PARK7/DJ-1*, *PARK2/PARKIN*, *PLA2G6*, *ATP13A2*, and *FBXO7* cause autosomal recessive PD and/or parkinsonism [74]. Despite being extensively studied, the gun trigger that causes PD remains unknown. An appraisal of the literature points towards a complex multifactorial etiology, in which a multiplicity of pathological *stimuli* contributes to the neurodegenerative cascade. So far, the main causes include impaired calcium homeostasis, iron overload, inflammation, protein aggregation, and defective metabolism [75]. In addition, several studies showed that oxidative stress can cause neuronal death and mitochondrial dysfunction [76].

The motor dysfunction observed in PD is linked to the loss of dopaminergic neurons in specific areas of the *substantia nigra pars compacta* (SNpc) region of the midbrain, which contributes to severe dopamine (DA) deficiency in the putamen and the caudate nucleus [77]. The cell bodies of nigrostriatal neurons are in the SNpc and their axon terminals

are projected to the dorsal striatum (i.e., putamen and caudate nucleus) (Figure 3A) [5,72]. Dopamine synthesized in this brain region is directed to the striatum and frontal cortex, allowing for the control of the musculoskeletal system and movement. Therefore, the degeneration of dopaminergic neurons leads to a decrease in DA levels. Symptoms of PD only develop after the loss of 50–60% of nigral neurons and the depletion of 70–85% of DA levels [67,78]. Although the neuropathology of PD is primarily characterized by dopaminergic neuron loss, neurodegeneration also extends to other neurotransmitter systems [68]. Indeed, cholinergic (nucleus basalis of Meynert, dorsal nucleus of vagus), serotonergic (raphe), and noradrenergic (locus coeruleus) neurons are also affected [79].



**Figure 3.** Major hallmarks of Parkinson’s disease. (A) Degeneration of nigrostriatal dopaminergic neurons. (B) Formation of Lewy inclusions. Adapted from [80,81].

One pathological hallmark of PD is the formation of Lewy bodies, which are lamellated and fibrillated aggregates that include  $\alpha$ -synuclein ( $\alpha$ Syn) and ubiquitin [82]. The accumulation of  $\alpha$ Syn results in the death of dopaminergic neurons [83]. In dopaminergic neurons,  $\alpha$ Syn regulates the synthesis, storage, and release of DA [84].  $\alpha$ Syn is prone to form oligomeric and fibrillar bodies in the cytosol or associate to the cellular membrane [85]. The formation of  $\alpha$ Syn inclusions begins in the lower brainstem nuclei [86,87], spreads through the pons to the midbrain and basal forebrain and reaches the neocortex [86]. These inclusions may accumulate in neuronal perikarya (Lewy bodies) and neuronal processes (Lewy neurites) (Figure 3B) [88,89]. The presence of these aggregates is associated with the accumulation of synaptic vesicles, decreased DA release, the impairment of degradation pathways, and increased oxidative stress [84].

#### 4. Pharmacotherapy of Alzheimer’s and Parkinson’s Diseases

Neurodegeneration is a complex process resulting from multiple defects [90]. The most obvious pathological features of AD and PD include the selective loss of neuronal populations with a consequent decrease in neurotransmitter levels, and the formation

of protein aggregates [66,91]. These observations led to the identification of the primary brain enzymatic targets (e.g., cholinesterases (ChEs), monoamine oxidases (MAOs), and catechol-*O*-methyltransferase (COMT)) [90], which are related to the regulation of neurotransmitter levels, and to the subsequent development of the currently available therapeutic agents [92,93].

#### 4.1. Targeting Neurotransmitter Depletion in Alzheimer's Disease

Cholinergic neurons are widely distributed in both the central and the peripheral nervous systems [48]. Although they represent less than 1% of neurons in the nervous system, almost every brain region and peripheral target receives cholinergic innervation [94]. Cholinergic neurons in the basal forebrain contain extensive cortical projections that are involved in the modulation of other neurotransmitter systems [95].


Studies focusing on the cholinergic system have received particular attention since the decline of cholinergic function was linked to age-related learning impairments and memory loss in AD [96]. The damage or the presence of abnormalities in cholinergic pathways, especially in the basal forebrain neurons, was correlated with the level of cognitive decline in late-stage AD patients [97]. Together with the loss of cholinergic markers, such as choline acetyltransferase (ChAT) and AChE, these observations led to the formulation of the “cholinergic hypothesis” [98], which states that the dysfunction of the cholinergic system contributes to the cognitive deficits in AD [99].

Acetylcholine (ACh) was the first neurotransmitter to be identified [100,101] and is widely distributed in the nervous system, playing important functional roles in attention, memory, learning, stress response, wakefulness and sleep, and sensory information [102]. The hippocampal and cortical levels of ACh in the brain of AD patients are decreased by approximately 90% [103]. It also has a very important role in the structural and functional remodeling of cortical circuits by establishing synaptic contacts in the networks of cells [104,105].

The synthesis of ACh is catalyzed by ChAT in the cytosol of presynaptic cholinergic neurons in a single-step reaction, in which choline and acetyl-coenzyme A (acetyl-CoA) are used as substrates (Figure 4) [106]. While acetyl-CoA is synthesized by mitochondria, choline is taken up from the extracellular space since it is not synthesized in neurons [107]. The rate-limiting step for the synthesis of ACh is the uptake of choline by the Na<sup>+</sup>-dependent, high-affinity choline transporter (ChT1) [108]. The neurotransmitter ACh is then accumulated in synaptic vesicles by the vesicular acetylcholine transporter (VAT). This transporter uses an electrochemical gradient generated by a proton adenosine triphosphate (ATP)ase to perform the uptake of one ACh molecule in exchange for two protons [107–109]. During neurotransmission, ACh is released from the presynaptic neuron into the synaptic cleft, where it binds to cholinergic receptors (muscarinic or nicotinic) in the postsynaptic and presynaptic membranes [106,110].

The action of ACh may persist for a long time due to the chemical stability of the neurotransmitter [111]. Therefore, the rapid hydrolysis of ACh by cholinesterases is a process to prevent cholinergic overactivation [112]. Two ChEs are present in mammals and can metabolize Ach: acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) [98]. While the Ch obtained from Ach inactivation is taken up by a pre-synaptic neuron via ChT1 [98,106,111], acetic acid is further decomposed [111].






**Figure 5.** Drugs in clinical use for AD treatment.

#### 4.2. Targeting Neurotransmitter Depletion in Parkinson's Disease

Dopamine is a catecholamine neurotransmitter present in the CNS and in some peripheral areas [126]. In the brain, DA transmission is associated with the control of fine motor movements and with cognitive functions that include learning, reward, attention, and decision-making [126,127]. The DA released in the nigrostriatal pathway is linked to the performance of voluntary movements, as well as the selection and initiation of suitable motor actions [128].

In the cytoplasm of the presynaptic dopaminergic neuron, DA biosynthesis occurs in two steps (Figure 6). The first step involves the hydroxylation of tyrosine into L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH), which is followed by a decarboxylation reaction catalyzed by aromatic amino acid decarboxylase (AADC) to afford DA [81,129]. The neurotransmitter is then transported into synaptic vesicles by the vesicular monoamine transporter (VMAT2) or metabolized by intraneuronal monoamine oxidase A (MAO-A) [130]. Following the release into the synaptic cleft, DA binds to the dopaminergic receptors present in the postsynaptic neuron [129]. The transport of the released DA into the presynaptic neuron occurs via a DA transporter (DAT) and is followed by DA recycling into the synaptic vesicles or by DA deamination by MAO-A. Alternatively, the DA transported into non-dopaminergic post-synaptic neurons and glial cells is metabolized by MAO-B and COMT [130].



**Figure 6.** Enzymes and transporters involved in the synthesis, storage, and metabolism of dopamine. Abbreviations: 3-MT, 3-methoxytyramine; AADC, aromatic amino acid decarboxylase; COMT, catechol-O-methyltransferase; DA, dopamine; DAT, dopamine transporter; DOPAC, 3,4-Dihydroxyphenylacetic acid; HVA, homovanillic acid; L-DOPA, L-3,4-dihydroxyphenylalanine; MAO-A, monoamine oxidase A; MAO-B, monoamine oxidase B; TH, tyrosine hydroxylase; VMAT2, vesicular monoamine transporter. Adapted from [130,131].

The loss of nigrostriatal dopaminergic neurons is associated with the development of the motor symptoms of PD, namely the difficulty in initiating and terminating movements, gait disturbance, and muscular rigidity [128]. Therefore, to reduce the severity of motor handicaps, most PD therapies are based on enhancing the dopaminergic signaling [92,132].

The use of the DA precursor L-DOPA (Figure 7) remains the gold-standard treatment for PD [133]. Unlike DA, L-DOPA can cross the blood–brain barrier (BBB) and increase DA synthesis in the brain [129]. To prevent the peripheral metabolic activation to DA, L-DOPA is commonly administered with decarboxylase inhibitors (e.g., carbidopa and benserazide) [134]. Despite the efficacy of L-DOPA in ameliorating motor symptoms, its long-term use is associated with the progressive loss of efficacy together with motor fluctuations and dyskinesia [70,135].




Figure 7. Drugs in clinical use for PD treatment.

In addition to L-DOPA, other therapeutic approaches involve the use of selective MAO-B inhibitors (rasagiline, selegiline, safinamide), COMT inhibitors (entacapone, tolcapone and opicapone) [136,137], or the agonists of postsynaptic DA receptors (pramipexole, ropinirole, apomorphine) (Figure 7) [138,139].

Due to their pivotal role in neurotransmitter catabolism and their affinity for specific neurotransmitters, MAOs are considered attractive drug targets in the treatment of depression and NDs [140,141]. In particular, MAO-B is the main isozyme involved in DA metabolism in the aged Parkinsonian brain [142]. While MAO-A activity is maintained with aging, the activity and expression of MAO-B in the human brain increase approximately 4-fold in most brain areas such as the basal ganglia [142,143], possibly as a result of glial cell proliferation and the concomitant loss of neuronal cells [144]. The amplified MAO-B activity leads to nigrostriatal DA depletion and to a higher production of H<sub>2</sub>O<sub>2</sub> and toxic aldehydes, which contribute to increased oxidative stress and neuronal degeneration [142,143].

MAO-B inhibitors (Figure 7) are currently used in PD therapies to prevent DA catabolism and prolong the action of DA in the basal ganglia [145]. The inhibition of MAO-B may also decrease the formation of dopamine-derived oxidative products, thereby delaying the disease progression [146]. Usually, MAO-B inhibitors are prescribed either as monotherapy or in combination with L-DOPA. Their use in monotherapy is more effective at the early stages of PD and may delay the use of L-DOPA [147]. When combined with L-DOPA, MAO-B inhibitors prolong the therapeutic effects of L-DOPA, decrease the dose of L-DOPA required to control the symptoms, and reduce the occurrence of L-DOPA-associated side effects [142,147].

COMT has received considerable attention due to its involvement in the metabolism of L-DOPA [148]. Given adjunctively with L-DOPA, COMT inhibitors (Figure 7) decrease L-DOPA premature inactivation, prolonging its half-life and improving its delivery to the brain [148,149]. In addition, COMT inhibitors enable a decrease in both the dose and administration frequency of L-DOPA, reducing “off” time (i.e., decreasing periods of time when symptoms are more noticeable and movements are more difficult) and increasing “on” time (i.e., increasing periods when PD patients experience good symptom control), thereby improving and prolonging the clinical response to L-DOPA [149].

Inhibitors of peripheral (entacapone, opicapone, Figure 7) and cerebral COMT (tolcapone, Figure 7) were developed and are available for the adjunctive treatment of PD. Peripheral COMT inhibition decreases the systemic decomposition of L-DOPA. Still, COMT inhibition in the CNS has the additional advantage of decreasing the metabolism of both L-DOPA and DA in the brain [130].

#### 4.3. Alzheimer's and Parkinson's Diseases: Looking for New Targets

Currently, the pharmacotherapy for AD and PD consists of drugs approved by the Food and Drug Administration (FDA) that regulate neurotransmitter levels. Unfortunately, they only provide valuable but modest symptomatic benefits, being unable to modify the course of these diseases [9,150]. These treatments are also accompanied by limitations. For instance, AChE inhibitors offer relatively short-lasting positive effects in AD patients [151] and display cholinomimetic actions on the gastrointestinal tract that result in diarrhea, nausea, and vomiting [152]. The efficacy of PD medicines also decreases over time, and the chronic treatment often culminates in motor complications (e.g., L-DOPA-induced dyskinesia) [153].

The need for beneficial neuroprotective agents has been the driving force for the development of new and innovative therapeutic strategies, preferably with disease-modifying outcomes. For instance, over the last years, efforts have been made to develop new drug candidates able to tackle increased oxidative stress, metal dyshomeostasis (iron, copper), neuroinflammation, and the aggregation of misfolded protein (Table 1). The following subsections will discuss the development of pharmacological agents targeting oxidative stress or the adenosine receptors in NDs as representative examples.

**Table 1.** Examples of therapeutic targets looked at for drug discovery and the development of AD and PD.

(Patho)physiological Process	Target	
	AD	PD
Metal dyshomeostasis	copper [154]; iron [155]; zinc [156]	Copper [157]; iron [158]
Mitochondria and metabolic functions	MCL1 [159]	ROCK [160], $\delta$ -opioid receptor [161]
Mutated/misfolded proteins	Amyloid- $\beta$ [162]; $\beta$ -secretase [163]; $\gamma$ -secretase [164]; GSK3- $\beta$ [165]; RAGE [166]; Tau [167]	DJ1 [168]; LRRK2 [169]; Pink1 [170]; $\alpha$ -synuclein [171]; CK1 $\delta$ [172]; CK1 $\delta$ +GSK3b [173]
Neuroinflammation	NRLP3 inflammasome [174]	Adenosine receptors [175]; cannabinoid receptor 2 [176]; monoacylglycerol lipase [177]; NRLP3 Inflammasome [178]; PPAR [179]; TRPC5 [180]
Neuroprotection	Apoptosis [181]; ferroptosis [182]; sigma 1 and 2 receptors [183]	Apoptosis [184]; autophagy/neuroinflammation [185]; CDNF peptidomimetic [186]; ferroptosis [187]; nurr1 [188]; sigma 1 and 2 receptors [189]
Oxidative stress	Antioxidants [190]; NRF2 signaling pathway [191]	Aldose reductase [192]; NRF2 signaling pathway [193]
Synaptic activity	AChE [110]; $\alpha$ 7nAChR [194]; butyrylcholinesterase [195]; NMDA receptor [196]	5-HT2A [197]; adenosine receptors [198,199]; $\alpha$ 6AChR [200]; COMT [201]; dopaminergic D1-D4 receptors [202–204]; GPR6 [205]; MAO-B [206]; mGlu4 [207]; PDE4 [208]

#### 4.3.1. Oxidative Stress as a Target in Alzheimer's and Parkinson's Diseases


Oxidative stress is one of the major contributors to the pathogenic cascade that leads to neurodegeneration in AD and PD [209,210]. Evidence of reactive oxygen species (ROS)-mediated injuries, with increased levels of oxidative markers and damaged cell components, were observed in AD and PD brains [211]. A decline in the pool of endogenous antioxidants and a decrease in the activity of antioxidant enzymes were also reported [25,212].

The brain is particularly prone to oxidative stress-induced damage. Although the brain constitutes only ~2% of the total body weight, it is responsible for more than 20% of the body's oxygen consumption, with a significant amount of oxygen being converted into ROS [210,213,214]. Despite this massive oxygen consumption, the brain presents a lower content of endogenous antioxidants (e.g., glutathione and catalase) in comparison to other tissues, thus being more sensitive to cellular redox dyshomeostasis [213,215]. In addition, redox-active metals (e.g., iron and copper) accumulate in specific brain regions and catalyze the formation of ROS [122,210]. Finally, the high levels of polyunsaturated fatty acids in the brain increase the susceptibility to lipid peroxidation and subsequent formation of toxic compounds [210,213,216].


The increased oxidative stress in NDs is strictly connected to other pathological events, namely mitochondrial dysfunction, dopamine oxidation, neuroinflammation, and the accumulation of protein aggregates (e.g., A $\beta$  and  $\alpha$ -syn) (Figure 8) [217].

Although ROS are generated in several cellular compartments, mitochondria is one of the main sources of the overproduction of ROS [123]. The formation of ROS in mitochondria occurs primarily at the ETC present in the inner mitochondrial membrane (Figure 9) [124,210]. The mitochondrial ETC consists of a series of membrane-bound complexes (complexes I, II, III and IV) [119], which generate a proton gradient across the inner mitochondrial membrane through electron transfers, leading to the production of ATP by ATP synthase (complex V) [210]. Metabolic intermediates formed during the Krebs cycle are used for oxidative phosphorylation [120]. During the ETC, a small proportion of electrons

occasionally leak and directly reduce  $O_2$  to  $O_2^{\bullet-}$  [120,121], which is, in turn, converted into other ROS such as  $H_2O_2$  and  $HO^{\bullet}$  [123]. The formation of  $O_2^{\bullet-}$  occurs mainly in complexes I and III [121,218]. Enzymes from the Krebs cycle (e.g.,  $\alpha$ -ketoglutarate dehydrogenase, pyruvate dehydrogenase, and aconitase) may also generate ROS [218,219].



**Figure 8.** Pathological events of neurodegenerative diseases associated with increased oxidative stress.




**Figure 9.** Formation of ROS in mitochondria. Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; CAT, catalase; Cyt C, Cytochrome C; GPx, Glutathione peroxidase; I, complex I; II, complex II; III, complex III; IV, complex IV; NADH, Nicotinamide adenine dinucleotide; Q, coenzyme Q10; SOD1, superoxide dismutase 1; SOD2, superoxide dismutase 2; V, complex V (ATP synthase). Adapted from [119,220].

Mitochondrial ETC is one of the primary targets of the harmful effects inflicted by high levels of ROS [119,221]. The oxidative damage at this level leads to the inhibition of ATP synthesis and the increased production of ROS in a vicious and detrimental cycle, contributing to cell dysfunction and cell death [124,221,222]. Mitochondria contain other components susceptible to oxidative damage, namely several iron-sulfur centers, proteins and unsaturated fatty acids in the inner membrane, and mitochondrial DNA (mtDNA), all of which are important for proper mitochondrial function [124]. Considering that mtDNA encodes some of the subunits of the complexes that constitute the ETC, the oxidative damage of mtDNA leads to the defective production of these proteins and subsequent mitochondrial dysfunction [221].

Since neurons have limited glycolytic capacity, they are particularly dependent on mitochondrial oxidative phosphorylation to meet their high energy requirements [222–224]. In addition to ATP synthesis, mitochondria are involved in other crucial cellular functions such as the synthesis of amino acids and steroids,  $\beta$ -oxidation of fatty acids,  $\text{Ca}^{2+}$  homeostasis, and the regulation of apoptotic cell death [225]. Therefore, improper mitochondrial function compromises neuronal survival and contributes to neurodegeneration [219,225].

In PD, DA oxidation is associated with a selective vulnerability of dopaminergic neurons to oxidative stress [220]. Despite the essential role of DA in neurotransmission, DA contains a catechol group that may participate in the generation of ROS and metal chelation [226]. Dopamine is normally stored in monoaminergic vesicles under a low pH environment that prevents its oxidation [227]. However, DA may undergo enzymatic and non-enzymatic decomposition in the cytosol, which is accompanied by the formation of ROS (Figure 10) [228].



**Figure 10.** Generation of ROS during enzymatic (dashed line) and non-enzymatic (plain line) DA decomposition. Abbreviations: ALDH, aldehyde dehydrogenase; COMT, catechol O-methyltransferase; DA, dopamine; DA-quinone, dopamine quinone; MAO, monoamine oxidase, NAD(P)H, nicotinamide adenine dinucleotide (phosphate). Adapted from [229].

In the presence of  $O_2$ , DA generates  $O_2^{\bullet-}$  and electron-deficient DA semiquinones and DA quinones (Figure 10) [228,230,231]. The reaction rate of DA semiquinone formation is slow, but it is accelerated by redox-active transition metals [215]. The spontaneous cyclization of DA quinone yields leucoaminochrome whose further autoxidation forms aminochrome and  $O_2^{\bullet-}$  [230]. Aminochrome participates in redox-cycling reactions that result in the formation of  $O_2^{\bullet-}$  and in the depletion of cellular nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) [232]. Dopamine quinone and aminochrome also form adducts, with cellular nucleophiles modifying their function [233,234]. These include DNA, biothiols (e.g., glutathione),  $\alpha$ -synuclein and proteins involved in ATP synthesis (complexes I, III and V of the ETC), proteasomal degradation (parkin), microtubule stabilization ( $\alpha$ - and  $\beta$ -tubulin) and axonal transport (actin) [229]. Therefore, the formation of these adducts will contribute to mitochondrial dysfunction, the impairment of the axonal transport, the inhibition of the proteasomal system, the disruption of cytoskeleton architecture, and the formation of  $\alpha$ -synuclein aggregates in PD [229]. Aminochrome also polymerizes into neuromelanin, a brain pigment that contributes to neurodegeneration by triggering neuroinflammatory processes [210].

The oxidative deamination of DA by MAOs uses  $O_2$ , and generates  $H_2O_2$  and ammonia as by-products (Figure 10) [235]. Due to the increased expression with age in neuronal tissue [102,236], MAO-B becomes the predominant isoform involved in DA metabolism [210]. Monoamine oxidase B is mainly found in glial cells [105,237], but the  $H_2O_2$  produced during DA deamination can permeate cell membranes and induce toxic effects in the neighboring neurons [210]. In fact, compared with astrocytes, neurons are more vulnerable to  $H_2O_2$  due to the lower content in antioxidants involved in its detoxification (e.g., GPx and glutathione) [237]. The  $H_2O_2$  generated from MAO-B activity in astrocytes is also associated with increased amyloid plaque deposition [111].

Neuroinflammation represents a set of inflammatory processes occurring in the central nervous system that involve the action of glial cells in CNS (microglia, oligodendrocytes, astrocytes), non-glial resident myeloid cells (macrophages and dendritic cells) and peripheral leukocytes [238,239]. Neuroinflammation plays an important role in the progression of NDs [228]. For instance, in AD, microglia are activated by the presence of  $A\beta$  and co-localize with the plaques [240]. However, instead of efficiently removing the  $A\beta$  deposits, microglia release pro-inflammatory mediators that lead to neuronal damage [241]. In PD, extracellular  $\alpha$ SYN aggregates can also interact with and activate surrounding glial cells to trigger a deleterious pro-inflammatory response [242]. In NDs, the expression of NADPH oxidases (NOXs) in activated microglia and reactive astrocytes is increased, resulting in the excessive formation of  $O_2^{\bullet-}$  [228,243]. The activation of RS-producing enzymes in glial cells is associated with neurotoxic effects, which arise not only from the direct oxidative damage in neurons, but also from the intracellular redox signaling that exacerbates the pro-inflammatory response [243,244].

#### Targeting Oxidative Stress with Mitochondria-Targeted Antioxidants


Considering the involvement of oxidative stress in the pathophysiology of NDs, the rationale for using exogenous antioxidants to prevent delay or remove the oxidative damage is evident [214,245]. In fact, several exogenous antioxidants showed promising results in animal and cellular models [213,214]. However, the results obtained in clinical trials were inconclusive, negative, or showed little benefit in NDs [246]. Numerous factors contribute to the discrepancy between pre-clinical and clinical results. In addition to the aspects associated with the design of clinical trials (e.g., posology, the duration of treatment, age, and the disease stage of the patients), most known dietary antioxidants display poor bioavailability and are unable to cross the BBB, affecting their delivery into the brain [213,214,246,247].

A common strategy used to overcome these pharmacokinetic limitations is the introduction of minor structural modifications on the antioxidant scaffold. The resulting

derivatives may improve the targeting and drug-like properties while preserving or enhancing the antioxidant profile of the parent compounds [248,249].

Aside from the pharmacokinetic constraints, the lack of the clinical efficacy of antioxidants may also result from the uniform distribution of antioxidants across all tissues and organs following administration, with only a small fraction being taken up by mitochondria [246,250], the main source and the target of ROS. Therefore, the development of antioxidants that selectively accumulate within mitochondria and tackle oxidative damage is of particular interest [251]. Compounds lacking mitochondriotropism but with relevant biological activities towards mitochondrial targets usually need to be directed to mitochondria [252]. In this sense, several approaches were developed to deliver antioxidants and other bioactive molecules to mitochondria, but one of the most widely used is their conjugation with lipophilic cations such as triphenylphosphonium (TPP<sup>+</sup>) [251,253].

Lipophilic TPP<sup>+</sup> cations can diffuse across phospholipid bilayers because their positive charge is surrounded and dispersed over a large hydrophobic surface area, which decreases the activation energy for membrane permeation [254–256]. In response to the plasma and mitochondrial membrane potentials ( $\Delta\Psi_{plasma}$  and  $\Delta\Psi_{mitochondria}$ , respectively), these compounds accumulate within the mitochondrial matrix against the concentration gradient [254] (Figure 11A). Then, TPP<sup>+</sup> conjugates are taken up from the intracellular space to the mitochondrial matrix in response to the  $\Delta\Psi_{mitochondria}$  (−140 to −160 mV), leading to 100- to 500-fold accumulation within the mitochondrial matrix [220,256].



**Figure 11.** (A) Mitochondrial uptake of lipophilic cations. (B) Representative examples of lipophilic cations to target bioactive molecules to mitochondria. Adapted from [255,257].

The increased accumulation of lipophilic TPP<sup>+</sup> conjugates enhances the compounds' potency and decreases the external dose required, limiting the extramitochondrial metabolism that results in inactivation, excretion, or toxicity [124,258]. However, the extensive accumulation of these compounds within the mitochondrial matrix can disrupt membrane integrity, thereby compromising cellular respiration and ATP production [259,260].


Following oral or intravenous administration, lipophilic TPP<sup>+</sup> conjugates are rapidly taken up by the organs most affected by mitochondrial dysfunction (e.g., liver, heart,

and brain) [254,261]. Therefore, targeting antioxidants in mitochondria stands out as a promising strategy in the discovery of new therapies for oxidative stress-related disorders.

Over the last decade, TPP<sup>+</sup> cations have been conjugated with dietary antioxidants such as hydroxybenzoic [262] and hydroxycinnamic acids [263]. These compounds displayed remarkable antioxidant properties and were able to protect neuroblastoma cells against the oxidative damage induced by 6-hydroxydopamine or H<sub>2</sub>O<sub>2</sub> [264]. Moreover, in studies performed in skin fibroblasts from male sporadic PD (sPD) patients, the caffeic acid-based TPP<sup>+</sup> conjugate AntiOXCIN4 restored mitochondrial membrane potential and mitochondrial fission, decreased autophagic flux, and enhanced cellular responses to stress by improving the cellular redox state and decreasing ROS levels [265]. To circumvent the drawbacks associated with the use of the TPP<sup>+</sup> cation, its replacement with nitrogen-based cationic carriers (e.g., isoquinolinium, imidazolium, and picolinium) was recently performed (Figure 11B) [266]. This chemical modification resulted in decreased cytotoxicity while maintaining the compounds' antioxidant properties and their ability to accumulate within mitochondria [266].

#### 4.3.2. Adenosine Receptors as a Target in Alzheimer's and Parkinson's Diseases

Adenosine is a purine nucleoside that may act as a neurotransmitter as neuromodulator in the CNS [267]. It is involved in several physiological and pathophysiological processes in the brain, including motor function, sleep/wake cycle, learning and memory, pain, and astrocytic activity [268]. To perform its physiological roles, adenosine binds to four distinct G-coupled protein adenosine receptors (ARs), designated as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub>. Adenosine receptors (ARs) represent a group of glycoproteins containing seven transmembrane domains and are coupled to different G proteins [269] (Figure 12). While adenosine A<sub>1</sub> and A<sub>3</sub> receptors are coupled to inhibitory G proteins, A<sub>2A</sub> and A<sub>2B</sub> ARs are coupled to stimulatory G proteins. The A<sub>2A</sub> and A<sub>2B</sub> ARs preferably interact with members of the G<sub>s</sub> family of G proteins, stimulating adenylyl cyclase to produce cyclic AMP (cAMP) and leading to the activation of a series of downstream signaling pathways. In contrast, A<sub>1</sub> and A<sub>3</sub> ARs inhibit adenylyl cyclase activity by interacting with G<sub>i</sub> proteins (Figure 12) [270].



**Figure 12.** Schematic representation of G protein-coupled adenosine receptors.

ARs are widely distributed in the human body and participate in a broad range of physiological and pathophysiological processes [198]. While A<sub>1</sub>Rs and A<sub>2</sub>Rs can be predominantly found in specific parts of the CNS, A<sub>2B</sub>Rs and A<sub>3</sub>Rs are mainly located in peripheral tissues [271].


In the CNS, A<sub>1</sub>Rs are widely distributed in neocortical and limbic systems and are linked to cognitive functions [198,272,273]. A<sub>2A</sub>Rs are highly expressed in striatal areas [198,272] and participate in the regulation of motor behavior and the management of dopamine-mediated responses [199]. A<sub>2A</sub>Rs co-localize with dopamine D<sub>2</sub> receptors (D<sub>2</sub>Rs) on GABAergic striatopallidal output neurons, where they form heteromer complexes [274]. These receptors within the heteromeric complex exert opposite effects on motor behavior, in which A<sub>2A</sub> AR agonism induces antagonistic effects on D<sub>2</sub>Rs. For instance, the stimulation of dopamine D<sub>2</sub>Rs enhances motor activity, while A<sub>2A</sub> ARs decrease this effect by decreasing the affinity and response of D<sub>2</sub>Rs to their ligands [273,275].

Excessive A<sub>2A</sub> AR function has been linked to neuronal damage [276], and increased A<sub>2A</sub> AR expression is a characteristic feature of PD progression [277]. The cellular mechanisms responsible for A<sub>2A</sub> AR-mediated neurodegeneration remain elusive. However, evidence suggests that the activation of A<sub>2A</sub> ARs leads to increased glutamate release, increased Ca<sup>2+</sup> entry, and enhanced long-term potentiation, all of which may culminate in excitotoxic damage [275]. The localization of A<sub>2A</sub> ARs at the basal ganglia, coupled with their pathophysiological role in PD, makes these receptors attractive drug targets to treat this disease [275]. A<sub>2A</sub> AR antagonism decreases motor impairment by enhancing dopamine D<sub>2</sub>R-mediated signaling. Moreover, A<sub>2A</sub> AR antagonism modulates cholinergic, glutamatergic, and GABAergic functions in the CNS [273]. The blockade of A<sub>2A</sub> AR signaling with selective A<sub>2A</sub> AR receptor antagonists was shown to be beneficial, not only by enhancing the therapeutic effects of L-DOPA, but also by reducing dyskinesia from long-term L-DOPA treatment [274].

Recent studies have also disclosed a close association between A<sub>2A</sub> ARs and cognitive impairment in AD. For instance, abnormally high levels of A<sub>2A</sub> AR were detected in the hippocampus and in the cortex of AD patients [266,278] and in APP/PS1 transgenic AD mice [279]. Remarkably, the activation of A<sub>2A</sub> ARs with agonists and optogenetic agents led to severe impairments in spatial discrimination in wild-type mice [280]. The involvement of A<sub>2A</sub> ARs in hippocampal-dependent spatial reference memory was also shown in A<sub>2A</sub> AR knock-out studies in an Aβ<sub>1-42</sub>-based mice model of AD [281]. The memory deficits in APP/PS1 mice were reverted by the blockade of A<sub>2A</sub> ARs with a selective antagonist or by downregulation driven with shRNA interference [279]. Finally, recently, it was shown that the improvement of spatial memory deficits by A<sub>2A</sub> AR antagonists in APP/PS1 mice results from the promotion of the synaptic plasticity of adult-born granule cells [282]. Thus, the blockade of A<sub>2A</sub> AR activation with selective antagonists can be of great therapeutic benefit to AD patients.

#### A<sub>2A</sub> Adenosine Receptor Antagonists

The knowledge acquired over the last decades concerning the involvement of adenosine in motor functions, mainly through the modulation of A<sub>2A</sub> AR, makes A<sub>2A</sub> AR antagonists promising non-dopaminergic agents for the treatment of PD motor symptoms. Over the last decades, the development of potent and selective ligands for ARs has been a dynamic area. Excellent reviews were recently published on this topic [283,284]. A small number of selective A<sub>2A</sub> AR antagonists reached advanced clinical trials for the treatment of motor symptoms in PD, namely the xanthine derivative istradefylline (KW-6002) and the non-xanthine derivatives Tozadenant (SYN115), Preladenant, and KW-6356 (Figure 13) [272,277].



**Figure 13.** Chemical structures of selective A<sub>2A</sub> AR antagonists evaluated in clinical trials.

Istradefylline was approved for the adjunctive treatment of PD in Japan in 2013 and by the FDA in 2019, being the first non-dopaminergic drug approved by the FDA for PD in the last two decades [285]. Preladenant and Tozadenant underwent clinical evaluation for the treatment of PD (Preladenant: NCT00406029, NCT01227265; Tozadenant: NCT02453386, NCT03051607) [286]. Unfortunately, the clinical evaluation for both drug candidates was discontinued due to the lack of efficacy (Preladenant) or safety (Tozadenant) in phase 3 clinical trials [287].

KW-6356 is a new, selective, nonxanthine A<sub>2A</sub> receptor antagonist/inverse agonist. Compared to istradefylline, KW-6356 exhibits approximately 100-times higher affinity for the human A<sub>2A</sub> receptor and a prolonged drug residence time [288]. In a phase 2b clinical study in patients with PD, KW-6356 was safe and effective in the adjunctive treatment with L-DOPA (NCT03703570) [289]. Moreover, in a phase 2a clinical trial, KW-6356 monotherapy was well tolerated and more effective than placebo in patients with early, untreated PD (NCT02939391) [277].

## 5. Conclusions

The discovery of new drugs for NDs remains an enormous unmet medical need [290]. The available treatments for AD and PD provide valuable symptomatic relief, but only reduce the symptoms for a short period before the cognitive or motor functions continue to deteriorate [291]. Given the lack of therapeutic efficacy in current treatments, the use of single-target drugs may be insufficient to address the multiple pathological aspects of NDs [292]. The treatment of AD and PD may thus require the manipulation of several targets to restore physiological balance, thereby attaining significant therapeutic efficacy [293].

Traditionally, the “one-drug, one-target” paradigm is the mainstay drug discovery concept in the pharmaceutical industry [91]. This paradigm is mainly focused on generating drugs that selectively bind to a single biological target, avoiding potential adverse side effects associated with mistargeting other biological entities [294]. The current therapy for AD and PD management is based on this paradigm. However, current single-target drugs address the diseases’ symptomatology, without halting or modifying the disease progression [294,295]. Therefore, drugs that can simultaneously manipulate multiple targets may provide therapeutic benefits in AD and PD diseases due to their multifactorial nature and complexity [296]. The limited clinical efficacy and the lack of disease-modifying effects of the available drugs shifted the research focus from single-target agents to multitarget-directed drugs [237,247]. The field of the multitarget approach may thus provide innovative

therapeutic solutions to feed the pipeline of disease-modifying drugs for AD and PD. The potential of the multitarget approach in discovering new drug candidates for multifactorial diseases such as AD and PD was extensively reviewed in [294,297,298].

Over the last decades, continuous efforts have been made to unveil the pathological mechanisms underlying AD and PD development. Processes such as oxidative stress, metal dyshomeostasis, neuroinflammation, and protein misfolding and aggregation were identified, and new pathological events were discovered daily. As a result, promising drug targets have been emerging, providing excellent opportunities to innovate in developing new drug candidates. Thus, where do we go now? With the growing popularity of the multitarget paradigm, the possibilities are endless, and several paths can be followed. Medicinal chemists can explore multiple combinations of pharmacological effects in the search for disease-modifying drugs with a multitarget mode of action. Another emerging area is the development of new chemical modalities such as protein degraders. Targeted protein degradation (TDP) technologies include proteolysis-targeting chimeras (PROTACs), autophagy-targeting chimeras (AUTACs), and autophagosome-anchoring chimeras (AT-ACCs). Although the application of TDP technologies for NDs is still in its infancy, recent studies have shown that their use is a strategy worth exploring [299,300]. The combination of TDP technologies with multitarget strategies is also a direction that can be followed.

**Author Contributions:** Conceptualization: L.S., F.B. and D.C.; Writing—original draft preparation: L.S., S.B., C.F., A.G. and D.C.; Writing—review and editing: L.S., S.B., C.F., I.L., J.P., C.A., C.S.M., A.G., F.B. and D.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by FEDER funds through the Operational Programme Competitiveness Factors COMPETE and national funds by the Foundation for Science and Technology (FCT), I.P., under research grants PT-OPENSREEN-NORTE-01-0145-FEDER-085468, LA/P/0058/2020 (<https://doi.org/10.54499/LA/P/0056/2020>), UIDB/00081/2020 (<https://doi.org/10.54499/UIDB/00081/2020>) and UIDP/00081/2020 (<https://doi.org/10.54499/UIDP/00081/2020>). Grants are supported by FCT, MCTES, Fundo Social Europeu (FSE), and UE. L. Sequeira, S. Benfeito, C. Fernandes (project reference 2021.04016.CEECIND/CP1655/CT0004 and DOI identifier 10.54499/2021.04016.CEECIND/CP1655/CT0004), A. Gaspar and D. Chavarria grants are supported by FCT and FEDER/COMPETE.

**Acknowledgments:** The authors would like to thank FCT, MCTES, Fundo Social Europeu (FSE), and UE for the financial support. C. Fernandes thanks the FCT for the financial support of his work contract through the Scientific Employment Stimulus—Individual Call (2021.04016.CEECIND/CP1655/CT0004). A. Gaspar thanks the FCT for financial support through contract DL 57/2016/CP1454/CT0008 (DOI: 10.54499/DL57/2016/CP1454/CT0008).

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Moutinho, M.; Codocedo, J.F.; Puntambekar, S.S.; Landreth, G.E. Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation. *Annu. Rev. Pharmacol. Toxicol.* **2019**, *59*, 237–261. [[CrossRef](#)] [[PubMed](#)]
2. Feigin, V.L.; Vos, T.; Nichols, E.; Owolabi, M.O.; Carroll, W.M.; Dichgans, M.; Deuschl, G.; Parmar, P.; Brainin, M.; Murray, C. The global burden of neurological disorders: Translating evidence into policy. *Lancet Neurol.* **2020**, *19*, 255–265. [[CrossRef](#)] [[PubMed](#)]
3. Fereshtehnejad, S.M.; Vosoughi, K.; Heydarpour, P.; Sepanlou, S.G.; Farzadfar, F.; Tehrani-Banihashemi, A.; Malekzadeh, R.; Sahraian, M.A.; Vollset, S.E.; Naghavi, M.; et al. Burden of Neurodegenerative Diseases in the Eastern Mediterranean Region, 1990–2016: Findings from the Global Burden of Disease 2016 Study. *Eur. J. Neurol.* **2019**, *26*, 1252–1265. [[CrossRef](#)] [[PubMed](#)]
4. van Bokhoven, P.; de Wilde, A.; Vermunt, L.; Leferink, P.S.; Heetveld, S.; Cummings, J.; Scheltens, P.; Vijverberg, E.G.B. The Alzheimer's disease drug development landscape. *Alzheimer's Res. Ther.* **2021**, *13*, 186. [[CrossRef](#)] [[PubMed](#)]
5. Lengyel-Zhand, Z.; Puentes, L.N.; Mach, R.H. PARKINSON'S: From cellular mechanisms to potential therapeutics. *Pharmacol. Ther.* **2022**, *230*, 107968. [[CrossRef](#)] [[PubMed](#)]
6. Gan, L.; Cookson, M.R.; Petrucelli, L.; La Spada, A.R. Converging pathways in neurodegeneration, from genetics to mechanisms. *Nat. Neurosci.* **2018**, *21*, 1300–1309. [[CrossRef](#)] [[PubMed](#)]
7. Coppède, F. The potential of epigenetic therapies in neurodegenerative diseases. *Front Genet* **2014**, *5*, 1–8. [[CrossRef](#)] [[PubMed](#)]
8. Burns, S.; Selman, A.; Sehar, U.; Rawat, P.; Reddy, A.P.; Reddy, P.H. Therapeutics of Alzheimer's Disease: Recent Developments. *Antioxidants* **2022**, *12*, 2402. [[CrossRef](#)]
9. Hill, D.R.; Hutters, A.D.; Towne, T.B.; Reddy, R.E.; Fogle, J.L.; Voight, E.A.; Kym, P.R. Parkinson's Disease: Advances in Treatment and the Syntheses of Various Classes of Pharmaceutical Drug Substances. *Chem. Rev.* **2023**, *123*, 13693–13712. [[CrossRef](#)]

10. Partridge, L. Intervening in ageing to prevent the diseases of ageing. *Trends Endocrinol. Metab.* **2014**, *25*, 555–557. [[CrossRef](#)]
11. Guo, J.; Huang, X.; Dou, L.; Yan, M.; Shen, T.; Tang, W.; Li, J. Aging and aging-related diseases: From molecular mechanisms to interventions and treatments. *Signal Transduct. Target. Ther.* **2022**, *7*, 391. [[CrossRef](#)] [[PubMed](#)]
12. Logroscino, G.; Urso, D.; Savica, R. Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions? *Neuroepidemiology* **2022**, *56*, 309–318. [[CrossRef](#)] [[PubMed](#)]
13. Zaib, S.; Javed, H.; Khan, I.; Jaber, F.; Sohail, A.; Zaib, Z.; Mehboob, T.; Tabassam, N.; Ogaly, H.A. Neurodegenerative Diseases: Their Onset, Epidemiology, Causes and Treatment. *ChemistrySelect* **2023**, *8*, e202300225. [[CrossRef](#)]
14. Yuan, L.; Guo, Y.; Wen, S.; Deng, H. Editorial: Genetic and Epigenetic Basis of Neurodegenerative Diseases. *Front. Aging Neurosci.* **2022**, *14*, 958847. [[CrossRef](#)] [[PubMed](#)]
15. United Nations. *World Population Ageing 2020 Highlights: Living Arrangements of Older Persons*; UN: New York, NY, USA, 2021.
16. Wyss-Coray, T. Ageing, neurodegeneration and brain rejuvenation. *Nature* **2016**, *539*, 180–186. [[CrossRef](#)] [[PubMed](#)]
17. Fang, R.; Ye, S.; Huangfu, J.; Calimag, D.P. Music therapy is a potential intervention for cognition of Alzheimer’s Disease: A mini-review. *Transl. Neurodegener.* **2017**, *6*, 2. [[CrossRef](#)] [[PubMed](#)]
18. Lane, C.A.; Hardy, J.; Schott, J.M. Alzheimer’s Disease. *Eur. J. Neurol.* **2018**, *25*, 59–70. [[CrossRef](#)]
19. Wimo, A.; Winblad, B.; Aguero-Torres, H.; von Strauss, E. The Magnitude of Dementia Occurrence in the World. *Alz. Dis. Assoc. Dis.* **2003**, *17*, 63–67. [[CrossRef](#)] [[PubMed](#)]
20. Cahill, S. WHO’s global action plan on the public health response to dementia: Some challenges and opportunities. *Aging Mental Health* **2019**, *24*, 1–3. [[CrossRef](#)]
21. McFarthing, K.; Buff, S.; Rafaloff, G.; Fiske, B.; Mursaleen, L.; Fuest, R.; Wyse, R.K.; Stott, S.R.W. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. *J. Park. Dis.* **2023**, *13*, 427–439. [[CrossRef](#)]
22. Soilemezi, D.; Palmar-Santos, A.; Navarta-Sánchez, M.V.; Roberts, H.C.; Pedraz-Marcos, A.; Haahr, A.; Sørensen, D.; Bragstad, L.K.; Hjelle, E.G.; Haavaag, S.B.; et al. Understanding support systems for Parkinson’s disease management in community settings: A cross-national qualitative study. *Health Expect.* **2023**, *26*, 670–682. [[CrossRef](#)] [[PubMed](#)]
23. Winblad, B.; Amouyel, P.; Andrieu, S.; Ballard, C.; Brayne, C.; Brodaty, H.; Cedazo-Minguez, A.; Dubois, B.; Edvardsson, D.; Feldman, H.; et al. Defeating Alzheimer’s disease and other dementias: A priority for European science and society. *Lancet Neurol.* **2016**, *15*, 455–532. [[CrossRef](#)] [[PubMed](#)]
24. Parihar, M.S.; Hemnani, T. Alzheimer’s Disease pathogenesis and therapeutic interventions. *J. Clin. Neurosci.* **2004**, *11*, 456–467. [[CrossRef](#)] [[PubMed](#)]
25. Waldemar, G.; Dubois, B.; Emre, M.; Georges, J.; McKeith, I.G.; Rossor, M.; Scheltens, P.; Tariska, P.; Winblad, B. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. *Eur. J. Neurol.* **2007**, *14*, e1–e26. [[CrossRef](#)] [[PubMed](#)]
26. Taler, V.; Phillips, N.A. Language performance in Alzheimer’s disease and mild cognitive impairment: A comparative review. *J. Clin. Exp. Neuropsychol.* **2008**, *30*, 501–556. [[CrossRef](#)] [[PubMed](#)]
27. Alzheimer’s-Association. 2017 Alzheimer’s Disease Facts and Figures. *Alzheimer’s Dement.* **2017**, *13*, 325–373. [[CrossRef](#)]
28. López, O.L.; DeKosky, S.T. Clinical symptoms in Alzheimer’s disease. In *Handbook of Clinical Neurology*; Elsevier: Amsterdam, The Netherlands, 2008; Volume 89, pp. 207–216.
29. Scarmeas, N.; Brandt, J.; Albert, M.; Hadjigeorgiou, G.; Papadimitriou, A.; Dubois, B.; Sarazin, M.; Devanand, D.; Honig, L.; Marder, K.; et al. Delusions and Hallucinations Are Associated With Worse Outcome in Alzheimer Disease. *Arch. Neurol.* **2005**, *62*, 1601–1608. [[CrossRef](#)] [[PubMed](#)]
30. Tarawneh, R.; Holtzman, D.M. The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006148. [[CrossRef](#)] [[PubMed](#)]
31. Sang, Z.; Wang, K.; Dong, J.; Tang, L. Alzheimer’s disease: Updated multi-targets therapeutics are in clinical and in progress. *Eur. J. Med. Chem.* **2022**, *238*, 114464. [[CrossRef](#)]
32. Mohandas, E.; Rajmohan, V.; Raghunath, B. Neurobiology of Alzheimer’s disease. *Indian J. Psychiatry* **2009**, *51*, 55–61. [[CrossRef](#)]
33. Sloane, P.D.; Zimmerman, S.; Suchindran, C.; Reed, P.; Wang, L.; Boustani, M.; Sudha, S. The Public Health Impact of Alzheimer’s Disease, 2000–2050: Potential Implication of Treatment Advances. *Annu. Rev. Public Health* **2002**, *23*, 213–231. [[CrossRef](#)] [[PubMed](#)]
34. Corder, E.; Saunders, A.; Strittmatter, W.; Schmechel, D.; Gaskell, P.; Small, G.; Roses, A.; Haines, J.; Pericak-Vance, M. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. *Science* **1993**, *261*, 921–923. [[CrossRef](#)] [[PubMed](#)]
35. Strittmatter, W.J.; Saunders, A.M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G.S.; Roses, A.D. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. USA.* **1993**, *90*, 1977–1981. [[CrossRef](#)] [[PubMed](#)]
36. Blacker, D.; Haines, J.; Rodes, L.; Terwedow, H.; Go, R.; Harrell, L.; Perry, R.; Bassett, S.; Ga, C.; Meyers, D.; et al. ApoE-4 and Age at Onset of Alzheimer’s Disease: The NIMH Genetics Initiative. *Neurology* **1997**, *48*, 139–147. [[CrossRef](#)] [[PubMed](#)]
37. Rubinsztein, D.C. The genetics of Alzheimer’s disease. *Prog. Neurobiol.* **1997**, *52*, 447–454. [[CrossRef](#)] [[PubMed](#)]
38. Spire-Jones, T.L.; Hyman, B.T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. *Neuron* **2014**, *82*, 756–771. [[CrossRef](#)] [[PubMed](#)]
39. Mocerri, V.M.; Kukull, W.A.; Emanuel, I.; van Belle, G.; Larson, E.B. Early-life risk factors and the development of Alzheimer’s disease. *Neurology* **2000**, *54*, 415. [[CrossRef](#)] [[PubMed](#)]

40. Kivipelto, M.; Helkala, E.-L.; Laakso, M.P.; Hänninen, T.; Hallikainen, M.; Alhainen, K.; Soininen, H.; Tuomilehto, J.; Nissinen, A. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. *BMJ* **2001**, *322*, 1447–1451. [[CrossRef](#)] [[PubMed](#)]
41. Mucke, L. Alzheimer's Disease. *Nature* **2009**, *461*, 895. [[CrossRef](#)]
42. Bachurin, S.O.; Gavrilova, S.I.; Samsonova, A.; Barreto, G.E.; Aliev, G. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. *Pharmacol. Res.* **2017**, *129*, 216–226. [[CrossRef](#)]
43. Mattson, M.P. Pathways towards and away from Alzheimer's disease. *Nature* **2004**, *430*, 631–639. [[CrossRef](#)]
44. Bossy-Wetzel, E.; Schwarzenbacher, R.; Lipton, S.A. Molecular pathways to neurodegeneration. *Nat. Med.* **2004**, *10*, S2–S9. [[CrossRef](#)]
45. Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox Biol.* **2018**, *14*, 450–464. [[CrossRef](#)]
46. Venkateshappa, C.; Harish, G.; Mahadevan, A.; Srinivas Bharath, M.M.; Shankar, S.K. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: Implications for neurodegeneration in Alzheimer's disease. *Neurochem. Res.* **2012**, *37*, 1601–1614. [[CrossRef](#)]
47. Mufson, E.J.; Counts, S.E.; Perez, S.E.; Ginsberg, S.D. Cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. *Expert Rev. Neurother.* **2008**, *8*, 1703–1718. [[CrossRef](#)]
48. Kljacic, O.; Janickova, H.; Prado, V.F.; Prado, M.A.M. Cholinergic/glutamatergic co-transmission in striatal cholinergic interneurons: New mechanisms regulating striatal computation. *J. Neurochem.* **2017**, *142* (Suppl. S2), 90–102. [[CrossRef](#)]
49. Agrawal, M.; Biswas, A. Molecular diagnostics of neurodegenerative disorders. *Front. Mol. Biosci.* **2015**, *2*, 54. [[CrossRef](#)]
50. Ehret, M.J.; Chamberlin, K.W. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? *Clin. Ther.* **2015**, *37*, 1604–1616. [[CrossRef](#)]
51. Kovacs, G.G. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. *Int. J. Mol. Sci.* **2016**, *17*, 189. [[CrossRef](#)]
52. Pepeu, G.; Grazia Giovannini, M. The fate of the brain cholinergic neurons in neurodegenerative diseases. *Brain Res.* **2017**, *1670*, 173–184. [[CrossRef](#)]
53. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological Alterations in Alzheimer Disease. *Cold Spring Harb. Perspect. Med.* **2011**, *1*, a006189. [[CrossRef](#)]
54. Wisniewski, T.; Ghiso, J.; Frangione, B. Biology of A $\beta$  Amyloid in Alzheimer's Disease. *Neurobiol. Dis.* **1997**, *4*, 313–328. [[CrossRef](#)]
55. Stuchbury, G.; Münch, G. Alzheimer's associated inflammation, potential drug targets and future therapies. *J. Neural Transm.* **2005**, *112*, 429–453. [[CrossRef](#)]
56. Braak, H.; Braak, E. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories. *Neurobiol. Aging* **1997**, *18*, 351–357. [[CrossRef](#)]
57. Selkoe, D.J. Amyloid  $\beta$ -Protein and the Genetics of Alzheimer's Disease. *J. Biol. Chem.* **1996**, *271*, 18295–18298. [[CrossRef](#)]
58. Citron, M. Alzheimer's Disease: Strategies for disease modification. *Nat. Rev. Drug Discov.* **2010**, *9*, 387. [[CrossRef](#)]
59. Mandelkow, E.M.; Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006247. [[CrossRef](#)]
60. Kalra, J.; Khan, A. Reducing A $\beta$  load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. *Eur. J. Pharmacol.* **2015**, *764* (Suppl. C), 571–581. [[CrossRef](#)]
61. Pietrzik, C.; Behl, C. Concepts for the treatment of Alzheimer's disease: Molecular mechanisms and clinical application. *Int. J. Exp. Pathol.* **2005**, *86*, 173–185. [[CrossRef](#)]
62. Desai, A.K.; Grossberg, G.T. Diagnosis and treatment of Alzheimer's disease. *Neurology* **2005**, *64* (Suppl. S3), S34–S39. [[CrossRef](#)]
63. Santos, M.A.; Chand, K.; Chaves, S. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease. *Coordin. Chem. Rev.* **2016**, *327–328* (Suppl. C), 287–303. [[CrossRef](#)]
64. Cotman, C.W.; Su, J.H. Mechanisms of Neuronal Death in Alzheimer's Disease. *Brain Pathol.* **1996**, *6*, 493–506. [[CrossRef](#)]
65. Costa, H.N.; Esteves, A.R.; Empadinhas, N.; Cardoso, S.M. Parkinson's Disease: A Multisystem Disorder. *Neurosci. Bull.* **2023**, *39*, 113–124. [[CrossRef](#)]
66. Elmabruk, A.; Das, B.; Yedlapudi, D.; Xu, L.; Antonio, T.; Reith, M.E.A.; Dutta, A.K. Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease. *ACS Chem. Neurosci.* **2019**, *10*, 396–411. [[CrossRef](#)]
67. Jankovic, J. Parkinson's disease: Clinical features and diagnosis. *J. Neurol. Neurosurg. Psychiatry* **2008**, *79*, 368–376. [[CrossRef](#)]
68. Antony, P.M.; Diederich, N.J.; Kruger, R.; Balling, R. The hallmarks of Parkinson's disease. *Febs J.* **2013**, *280*, 5981–5993. [[CrossRef](#)]
69. Kalia, L.V.; Lang, A.E. Parkinson's disease. *Lancet* **2015**, *386*, 896–912. [[CrossRef](#)]
70. Zheng, J.; Zhang, X.; Zhen, X. Development of Adenosine A $_{2A}$  Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge. *ACS Chem. Neurosci.* **2019**, *10*, 783–791. [[CrossRef](#)]
71. Sanchez-Danes, A.; Richaud-Patin, Y.; Carballo-Carbajal, I.; Jimenez-Delgado, S.; Caig, C.; Mora, S.; Di Guglielmo, C.; Ezquerra, M.; Patel, B.; Giralt, A.; et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. *EMBO Mol. Med.* **2012**, *4*, 380–395. [[CrossRef](#)]
72. Abeliovich, A.; Gitler, A.D. Defects in trafficking bridge Parkinson's disease pathology and genetics. *Nature* **2016**, *539*, 207–216. [[CrossRef](#)]

73. Ryan, B.J.; Hoek, S.; Fon, E.A.; Wade-Martins, R. Mitochondrial dysfunction and mitophagy in Parkinson's: From familial to sporadic disease. *Trends Biochem. Sci.* **2015**, *40*, 200–210. [[CrossRef](#)]
74. Hernandez, D.G.; Reed, X.; Singleton, A.B. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. *J. Neurochem.* **2016**, *139* (Suppl. S1), 59–74. [[CrossRef](#)]
75. Jellinger, K.A. Recent advances in our understanding of neurodegeneration. *J. Neural Transm.* **2009**, *116*, 1111–1162. [[CrossRef](#)]
76. Subramaniam, S.R.; Chesselet, M.-F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. *Prog. Neurobiol.* **2013**, *17*–32. [[CrossRef](#)]
77. Oertel, W.; Schulz, J.B. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. *J. Neurochem.* **2016**, *139* (Suppl. S1), 325–337. [[CrossRef](#)]
78. Wirdefeldt, K.; Adami, H.O.; Cole, P.; Trichopoulos, D.; Mandel, J. Epidemiology and etiology of Parkinson's disease: A review of the evidence. *Eur. J. Epidemiol.* **2011**, *26* (Suppl. S1), S1–S58. [[CrossRef](#)]
79. Dauer, W.; Przedborski, S. Parkinson's disease: Mechanisms and models. *Neuron* **2003**, *39*, 889–909. [[CrossRef](#)]
80. Swanson, J.; Posner, M.; Fusella, J.; Wasdell, M.; Sommer, T.; Fan, J. Genes and attention deficit hyperactivity disorder. *Curr. Psychiatry Rep.* **2001**, *3*, 92–100. [[CrossRef](#)]
81. Brunelin, J.; Fecteau, S.; Suaud-Chagny, M.-F. Abnormal striatal dopamine transmission in schizophrenia. *Curr. Med. Chem.* **2013**, *20*, 397–404.
82. Erkkinen, M.G.; Kim, M.-O.; Geschwind, M.D. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb. Perspect. Biol.* **2017**, *10*, a033118. [[CrossRef](#)]
83. Yasuda, T.; Nakata, Y.; Mochizuki, H.  $\alpha$ -Synuclein and Neuronal Cell Death. *Mol. Neurobiol.* **2013**, *47*, 466–483. [[CrossRef](#)]
84. Melo, T.Q.; Copray, S.; Ferrari, M.F.R. Alpha-Synuclein Toxicity on Protein Quality Control, Mitochondria and Endoplasmic Reticulum. *Neurochem. Res.* **2018**, *43*, 2212–2223. [[CrossRef](#)]
85. Zhang, G.; Xia, Y.; Wan, F.; Ma, K.; Guo, X.; Kou, L.; Yin, S.; Han, C.; Liu, L.; Huang, J.; et al. New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease. *Front. Aging Neurosci.* **2018**, *10*, 370. [[CrossRef](#)]
86. Goedert, M. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A $\beta$ , tau, and  $\alpha$ -synuclein. *Science* **2015**, *349*, 1255555. [[CrossRef](#)]
87. Borland, M.K.; Trimmer, P.A.; Rubinstein, J.D.; Keeney, P.M.; Mohanakumar, K.; Liu, L.; Bennett, J.P., Jr. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. *Mol. Neurodegener.* **2008**, *3*, 21. [[CrossRef](#)]
88. Dickson, D.W. Parkinson's disease and parkinsonism: Neuropathology. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a009258. [[CrossRef](#)]
89. Volpicelli-Daley, L.A.; Gamble, K.L.; Schultheiss, C.E.; Riddle, D.M.; West, A.B.; Lee, V.M.Y. Formation of  $\alpha$ -synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. *Mol. Biol. Cell* **2014**, *25*, 4010–4023. [[CrossRef](#)]
90. Ramsay, R.R.; Majekova, M.; Medina, M.; Valoti, M. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. *Front. Neurosci.* **2016**, *10*, 375. [[CrossRef](#)]
91. Guzior, N.; Wieckowska, A.; Panek, D.; Malawska, B. Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease. *Curr. Med. Chem.* **2015**, *22*, 373–404. [[CrossRef](#)]
92. Shook, B.C.; Jackson, P.F. Adenosine A<sub>2A</sub> Receptor Antagonists and Parkinson's Disease. *ACS Chem. Neurosci.* **2011**, *2*, 555–567. [[CrossRef](#)]
93. Macdonald, I.R.; Rockwood, K.; Martin, E.; Darvesh, S. Cholinesterase inhibition in Alzheimer's disease: Is specificity the answer? *J. Alzheimers Dis.* **2014**, *42*, 379–384. [[CrossRef](#)]
94. Woolf, N.J.; Butcher, L.L. Cholinergic systems mediate action from movement to higher consciousness. *Behav. Brain Res.* **2011**, *221*, 488–498. [[CrossRef](#)]
95. Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.S.; Mamczarz, J.; Holloway, H.W.; Giordano, T.; et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer  $\beta$ -amyloid peptide in rodent. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 17213–17218. [[CrossRef](#)]
96. Lendvai, B. Cholinergic Transmission. In *Handbook of Neurochemistry and Molecular Neurobiology: Neurotransmitter Systems*; Lajtha, A., Vizi, E.S., Eds.; Springer: Boston, MA, USA, 2008; pp. 113–127.
97. Terry, A.V., Jr.; Buccafusco, J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. *J. Pharmacol. Exp. Ther.* **2003**, *306*, 821–827. [[CrossRef](#)]
98. Wilkinson, D.G.; Francis, P.T.; Schwam, E.; Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: The relationship between pharmacological effects and clinical efficacy. *Drugs Aging* **2004**, *21*, 453–478. [[CrossRef](#)]
99. Li, F.; Wang, Z.M.; Wu, J.J.; Wang, J.; Xie, S.S.; Lan, J.S.; Xu, W.; Kong, L.Y.; Wang, X.B. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease. *J. Enzym. Inhib. Med. Chem.* **2016**, *31* (Suppl. S3), 41–53. [[CrossRef](#)]
100. Contestabile, A. The history of the cholinergic hypothesis. *Behav. Brain Res.* **2011**, *221*, 334–340. [[CrossRef](#)]
101. Dale, H.H. The action of certain esters and ethers of choline, and their relation to muscarine. *J. Pharmacol. Exp. Ther.* **1914**, *6*, 147–190.
102. Du, X.; Wang, X.; Geng, M. Alzheimer's disease hypothesis and related therapies. *Transl. Neurodegener.* **2018**, *7*, 1–7. [[CrossRef](#)]

103. Di Giovanni, S.; Borloz, A.; Urbain, A.; Marston, A.; Hostettmann, K.; Carrupt, P.A.; Reist, M. *In vitro* screening assays to identify natural or synthetic acetylcholinesterase inhibitors: Thin layer chromatography versus microplate methods. *Eur. J. Pharm. Sci.* **2008**, *33*, 109–119. [[CrossRef](#)]
104. Berger-Sweeney, J. The cholinergic basal forebrain system during development and its influence on cognitive processes: Important questions and potential answers. *Neurosci. Biobehav. Rev.* **2003**, *27*, 401–411. [[CrossRef](#)] [[PubMed](#)]
105. Schliebs, R.; Arendt, T. The cholinergic system in aging and neuronal degeneration. *Behav. Brain Res.* **2011**, *221*, 555–563. [[CrossRef](#)] [[PubMed](#)]
106. Colović, M.B.; Krstić, D.Z.; Lazarević-Pašti, T.D.; Bondžić, A.M.; Vasić, V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. *Curr. Neuropharmacol.* **2013**, *11*, 315–335. [[CrossRef](#)]
107. Okuda, T.; Haga, T. High-affinity choline transporter. *Neurochem. Res.* **2003**, *28*, 483–488. [[CrossRef](#)] [[PubMed](#)]
108. Amenta, F.; Tayebati, S.K. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. *Curr. Med. Chem.* **2008**, *15*, 488–498. [[CrossRef](#)]
109. Prado, M.A.; Reis, R.A.; Prado, V.F.; de Mello, M.C.; Gomez, M.V.; de Mello, F.G. Regulation of acetylcholine synthesis and storage. *Neurochem. Int.* **2002**, *41*, 291–299. [[CrossRef](#)]
110. Ferreira-Vieira, T.H.; Guimaraes, I.M.; Silva, F.R.; Ribeiro, F.M. Alzheimer's disease: Targeting the Cholinergic System. *Curr. Neuropharmacol.* **2016**, *14*, 101–115. [[CrossRef](#)]
111. Pohanka, M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. *Int. J. Mol. Sci.* **2012**, *13*, 2219–2238. [[CrossRef](#)]
112. Reale, M.; Costantini, E.; Di Nicola, M.; D'Angelo, C.; Franchi, S.; D'Aurora, M.; Di Bari, M.; Orlando, V.; Galizia, S.; Ruggieri, S.; et al. Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: Implication in peripheral inflammation. *Sci. Rep.* **2018**, *8*, 1319. [[CrossRef](#)]
113. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's disease: Current status and new perspectives. *Lancet Neurol.* **2003**, *2*, 539–547. [[CrossRef](#)]
114. Winkler, J.; Thal, L.J.; Gage, F.H.; Fisher, L.J. Cholinergic strategies for Alzheimer's disease. *J. Mol. Med.* **1998**, *76*, 555–567. [[CrossRef](#)] [[PubMed](#)]
115. Pardo-Moreno, T.; González-Acedo, A.; Rivas-Domínguez, A.; García-Morales, V.; García-Cozar, F.J.; Ramos-Rodríguez, J.J.; Melguizo-Rodríguez, L. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. *Pharmaceutics* **2022**, *14*, 1117. [[CrossRef](#)]
116. Brus, B.; Kosak, U.; Turk, S.; Pislár, A.; Coquelle, N.; Kos, J.; Stojan, J.; Colletier, J.P.; Gobec, S. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. *J. Med. Chem.* **2014**, *57*, 8167–8179. [[CrossRef](#)] [[PubMed](#)]
117. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer's disease. *Arch. Pharmacol. Res.* **2013**, *36*, 375–399. [[CrossRef](#)] [[PubMed](#)]
118. Onor, M.L.; Trevisiol, M.; Aguglia, E. Rivastigmine in the treatment of Alzheimer's disease: An update. *Clin. Interv. Aging* **2007**, *2*, 17–32. [[CrossRef](#)] [[PubMed](#)]
119. Winblad, B.; Poritis, N. Memantine in severe dementia: Results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). *Int. J. Geriatr. Psychiatry* **1999**, *14*, 135–146. [[CrossRef](#)]
120. Reisberg, B.; Doody, R.; Stöffler, A.; Schmitt, F.; Ferris, S.; Möbius, H.J. Memantine in Moderate-to-Severe Alzheimer's Disease. *N. Engl. J. Med.* **2003**, *348*, 1333–1341. [[CrossRef](#)] [[PubMed](#)]
121. Bassil, N.; Thaipisuttikul, P.; Grossberg, G.T. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. *Expert Opin. Pharmacother.* **2010**, *11*, 1765–1771. [[CrossRef](#)] [[PubMed](#)]
122. Bliss, T.V.P.; Collingridge, G.L. A synaptic model of memory: Long-term potentiation in the hippocampus. *Nature* **1993**, *361*, 31. [[CrossRef](#)]
123. Sucher, N.J.; Awobuluyi, M.; Choi, Y.-B.; Lipton, S.A. NMDA receptors: From genes to channels. *Trends Pharmacol. Sci.* **1996**, *17*, 348–355. [[CrossRef](#)]
124. Greenamyre, J.T.; Porter, R.H. Anatomy and physiology of glutamate in the CNS. *Neurology* **1994**, *44* (Suppl. S8), S7–S13. [[PubMed](#)]
125. Folch, J.; Busquets, O.; Ettcheto, M.; Sánchez-López, E.; Castro-Torres, R.D.; Verdager, E.; Garcia, M.L.; Olloquequi, J.; Casadesús, G.; Beas-Zarate, C.; et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. *J. Alzheimer's Dis.* **2018**, *62*, 1223–1240. [[CrossRef](#)] [[PubMed](#)]
126. Rangel-Barajas, C.; Coronel, I.; Florán, B. Dopamine Receptors and Neurodegeneration. *Aging Dis.* **2015**, *6*, 349–368. [[PubMed](#)]
127. Tritsch, N.X.; Sabatini, B.L. Dopaminergic modulation of synaptic transmission in cortex and striatum. *Neuron* **2012**, *76*, 33–50. [[CrossRef](#)] [[PubMed](#)]
128. Lester, D.B.; Rogers, T.D.; Blaha, C.D. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. *CNS Neurosci. Ther.* **2010**, *16*, 137–162. [[CrossRef](#)] [[PubMed](#)]
129. Jones, D.R.; Moussaud, S.; McLean, P. Targeting heat shock proteins to modulate  $\alpha$ -synuclein toxicity. *Ther. Adv. Neurol. Disord.* **2014**, *7*, 33–51. [[CrossRef](#)] [[PubMed](#)]
130. Finberg, J.P.M. Inhibitors of MAO-B and COMT: Their effects on brain dopamine levels and uses in Parkinson's disease. *J. Neural Transm.* **2018**, *126*, 433–448. [[CrossRef](#)] [[PubMed](#)]

131. Godar, S.C.; Bortolato, M. Gene-sex interactions in schizophrenia: Focus on dopamine neurotransmission. *Front. Behav. Neurosci.* **2014**, *8*, 71. [[CrossRef](#)] [[PubMed](#)]
132. Morales-Garcia, J.A.; Susin, C.; Alonso-Gil, S.; Perez, D.I.; Palomo, V.; Perez, C.; Conde, S.; Santos, A.; Gil, C.; Martinez, A.; et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. *ACS Chem. Neurosci.* **2013**, *4*, 350–360. [[CrossRef](#)]
133. Shook, B.C.; Rassnick, S.; Wallace, N.; Crooke, J.; Ault, M.; Chakravarty, D.; Barbay, J.K.; Wang, A.; Powell, M.T.; Leonard, K.; et al. Design and characterization of optimized adenosine A(2)A/A(1) receptor antagonists for the treatment of Parkinson's disease. *J. Med. Chem.* **2012**, *55*, 1402–1417. [[CrossRef](#)]
134. Zanforlin, E.; Zagotto, G.; Ribaudo, G. The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases. *ACS Chem. Neurosci.* **2017**, *8*, 2356–2368. [[CrossRef](#)] [[PubMed](#)]
135. Rusiecka, I.; Ruczyński, J.; Kozłowska, A.; Backtrog, E.; Mucha, P.; Kocić, I.; Rekowski, P. TP10-Dopamine Conjugate as a Potential Therapeutic Agent in the Treatment of Parkinson's Disease. *Bioconjug. Chem.* **2019**, *30*, 760–774. [[CrossRef](#)] [[PubMed](#)]
136. Stefano, E.; Francesca, M.; Damiana, L.; Tatyana, D.S.; Raul, R.G. Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson's Disease and L-DOPA Treatment. *CNS Neurol. Disord. Drug Targets* **2012**, *11*, 251–263.
137. Berger, A.A.; Winnick, A.; Izygon, J.; Jacob, B.M.; Kaye, J.S.; Kaye, R.J.; Neuchat, E.E.; Kaye, A.M.; Alpaugh, E.S.; Cornett, E.M.; et al. Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes. *Health Psychol. Res.* **2022**, *10*, 36074. [[CrossRef](#)] [[PubMed](#)]
138. Huleatt, P.B.; Khoo, M.L.; Chua, Y.Y.; Tan, T.W.; Liew, R.S.; Balogh, B.; Deme, R.; Goloncser, F.; Magyar, K.; Sheela, D.P.; et al. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease. *J. Med. Chem.* **2015**, *58*, 1400–1419. [[CrossRef](#)] [[PubMed](#)]
139. Wang, Y.D.; Bao, X.Q.; Xu, S.; Yu, W.W.; Cao, S.N.; Hu, J.P.; Li, Y.; Wang, X.L.; Zhang, D.; Yu, S.S. A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway. *J. Med. Chem.* **2016**, *59*, 9062–9079. [[CrossRef](#)] [[PubMed](#)]
140. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs. *J. Med. Chem.* **2007**, *50*, 5848–5852. [[CrossRef](#)] [[PubMed](#)]
141. Hammuda, A.; Shalaby, R.; Rovida, S.; Edmondson, D.E.; Binda, C.; Khalil, A. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. *Eur. J. Med. Chem.* **2016**, *114*, 162–169. [[CrossRef](#)] [[PubMed](#)]
142. Booyesen, H.P.; Moraal, C.; Terre'Blanche, G.; Petzer, A.; Bergh, J.J.; Petzer, J.P. Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase. *Bioorg. Med. Chem.* **2011**, *19*, 7507–7518. [[CrossRef](#)]
143. Tzvetkov, N.T.; Stammer, H.G.; Neumann, B.; Hristova, S.; Antonov, L.; Gastreich, M. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. *Eur. J. Med. Chem.* **2017**, *127*, 470–492. [[CrossRef](#)]
144. Tripathi, R.K.P.; Ayyannan, S.R. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update. *Med. Res. Rev.* **2019**, *39*, 1603–1706. [[CrossRef](#)]
145. Robakis, D.; Fahn, S. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. *CNS Drugs* **2015**, *29*, 433–441. [[CrossRef](#)]
146. Tong, J.; Rathitharan, G.; Meyer, J.H.; Furukawa, Y.; Ang, L.C.; Boileau, I.; Guttman, M.; Hornykiewicz, O.; Kish, S.J. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. *Brain* **2017**, *140*, 2460–2474. [[CrossRef](#)]
147. Krishna, R.; Ali, M.; Moustafa, A.A. Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease. *Front. Aging Neurosci.* **2014**, *6*, 180. [[CrossRef](#)]
148. Palma, P.N.; Rodrigues, M.L.; Archer, M.; Bonifacio, M.J.; Loureiro, A.I.; Learmonth, D.A.; Carrondo, M.A.; Soares-da-Silva, P. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: Interactions with the active site and regioselectivity of O-methylation. *Mol. Pharmacol.* **2006**, *70*, 143–153. [[CrossRef](#)]
149. Solla, P.; Cannas, A.; Marrosu, F.; Marrosu, M.G. Therapeutic interventions and adjustments in the management of Parkinson disease: Role of combined carbidopa/levodopa/entacapone (Stalevo). *Neuropsychiatr. Dis. Treat.* **2010**, *6*, 483–490. [[CrossRef](#)]
150. Monteiro, A.R.; Barbosa, D.J.; Remião, F.; Silva, R. Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. *Biochem. Pharmacol.* **2023**, *211*, 115522. [[CrossRef](#)]
151. Wang, H.; Zhang, H. Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease. *ACS Chem. Neurosci.* **2019**, *10*, 852–862. [[CrossRef](#)]
152. Yiannopoulou, K.G.; Papageorgiou, S.G. Current and Future Treatments in Alzheimer Disease: An Update. *J. Cent. Nerv. Syst. Dis.* **2020**, *12*, 1179573520907397. [[CrossRef](#)]
153. Aradi, S.D.; Hauser, R.A. Medical Management and Prevention of Motor Complications in Parkinson's Disease. *Neurotherapeutics* **2020**, *17*, 1339–1365. [[CrossRef](#)]
154. Fasaie, K.D.; Abolaji, A.O.; Faloye, T.R.; Odunsi, A.Y.; Oyetayo, B.O.; Enya, J.I.; Rotimi, J.A.; Akinyemi, R.O.; Whitworth, A.J.; Aschner, M. Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. *J. Trace Elem. Med. Biol.* **2021**, *67*, 126779. [[CrossRef](#)]
155. Esmieu, C.; Guettas, D.; Conte-Daban, A.; Sabater, L.; Faller, P.; Hureau, C. Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Obtained from in Vitro Studies. *Inorg. Chem.* **2019**, *58*, 13509–13527. [[CrossRef](#)]

156. Wang, L.; Yin, Y.-L.; Liu, X.-Z.; Shen, P.; Zheng, Y.-G.; Lan, X.-R.; Lu, C.-B.; Wang, J.-Z. Current understanding of metal ions in the pathogenesis of Alzheimer's disease. *Transl. Neurodegener.* **2020**, *9*, 10. [CrossRef]
157. Cukierman, D.S.; Lázaro, D.F.; Sacco, P.; Ferreira, P.R.; Diniz, R.; Fernández, C.O.; Outeiro, T.F.; Rey, N.A. X1INH, an improved next-generation affinity-optimized hydrazonic ligand, attenuates abnormal copper(i)/copper(ii)- $\alpha$ -Syn interactions and affects protein aggregation in a cellular model of synucleinopathy. *Dalton Trans.* **2020**, *49*, 16252–16267. [CrossRef]
158. Xiao, Z.; Wang, X.; Pan, X.; Xie, J.; Xu, H. Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease. *Exp. Neurol.* **2024**, *372*, 114614. [CrossRef]
159. Cen, X.; Xu, X.; Xia, H. Targeting MCL1 to induce mitophagy is a potential therapeutic strategy for Alzheimer disease. *Autophagy* **2021**, *17*, 818–819. [CrossRef]
160. Moskal, N.; Riccio, V.; Bashkurov, M.; Taddese, R.; Datti, A.; Lewis, P.N.; Angus McQuibban, G. ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway. *Nat. Commun.* **2020**, *11*, 88. [CrossRef]
161. Xu, Y.; Zhi, F.; Mao, J.; Peng, Y.; Shao, N.; Balboni, G.; Yang, Y.; Xia, Y.  $\delta$ -opioid receptor activation protects against Parkinson's disease-related mitochondrial dysfunction by enhancing PINK1/Parkin-dependent mitophagy. *Aging* **2020**, *12*, 25035. [CrossRef]
162. Zhang, Y.; Chen, H.; Li, R.; Sterling, K.; Song, W. Amyloid  $\beta$ -based therapy for Alzheimer's disease: Challenges, successes and future. *Signal Transduct. Target. Ther.* **2023**, *8*, 248. [CrossRef]
163. Maia, M.A.; Sousa, E. BACE-1 and  $\gamma$ -Secretase as Therapeutic Targets for Alzheimer's Disease. *Pharmaceutics* **2019**, *12*, 41. [CrossRef]
164. Wolfe, M.S.  $\gamma$ -Secretase: Once and future drug target for Alzheimer's disease. *Expert Opin. Drug. Discov.* **2024**, *19*, 5–8. [CrossRef] [PubMed]
165. Lauretti, E.; Dincer, O.; Praticò, D. Glycogen synthase kinase-3 signaling in Alzheimer's disease. *Biochim. Biophys. Acta (BBA)—Mol. Cell Res.* **2020**, *1867*, 118664. [CrossRef] [PubMed]
166. Reddy, V.P.; Aryal, P.; Soni, P. RAGE Inhibitors in Neurodegenerative Diseases. *Biomedicines* **2023**, *11*, 1131. [CrossRef] [PubMed]
167. Giovannini, J.; Smeralda, W.; Jouanne, M.; Sopkova-de Oliveira Santos, J.; Catto, M.; Voisin-Chiret, A.S. Tau protein aggregation: Key features to improve drug discovery screening. *Drug Discov. Today* **2022**, *27*, 1284–1297. [CrossRef] [PubMed]
168. Sharan, S.; Kumar, P.; Ambasta, K.R. Discovery of Novel Compounds Targeting DJ-1 as Neuroprotectants for Parkinson's Disease by Virtual Screening and In Silico Method. *Curr. Comput.-Aided Drug Des.* **2021**, *17*, 351–359. [CrossRef] [PubMed]
169. Hatcher, J.M.; Zwirek, M.; Sarhan, A.R.; Vatsan, P.S.; Tonelli, F.; Alessi, D.R.; Davies, P.; Gray, N.S. Development of a highly potent and selective degrader of LRRK2. *Bioorg. Med. Chem. Lett.* **2023**, *94*, 129449. [CrossRef] [PubMed]
170. Mehellou, Y. Parkinson's Disease: Are PINK1 Activators Inching Closer to the Clinic? *ACS Med. Chem. Lett.* **2023**, *14*, 870–874. [CrossRef] [PubMed]
171. Wang, Q.; Yao, S.; Yang, Z.-X.; Zhou, C.; Zhang, Y.; Zhang, Y.; Zhang, L.; Li, J.-T.; Xu, Z.-J.; Zhu, W.-L.; et al. Pharmacological characterization of the small molecule 03A10 as an inhibitor of  $\alpha$ -synuclein aggregation for Parkinson's disease treatment. *Acta Pharmacol. Sin.* **2023**, *44*, 1122–1134. [CrossRef] [PubMed]
172. Cescon, E.; Bolcato, G.; Federico, S.; Bissaro, M.; Valentini, A.; Ferlin, M.G.; Spalluto, G.; Sturlese, M.; Moro, S. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1  $\delta$  Inhibitors. *ACS Med. Chem. Lett.* **2020**, *11*, 1168–1174. [CrossRef]
173. Redenti, S.; Marcovich, I.; De Vita, T.; Pérez, C.; De Zorzi, R.; Demitri, N.; Perez, D.I.; Bottegoni, G.; Bisignano, P.; Bissaro, M.; et al. A Triazolotriazine-Based Dual GSK-3 $\beta$ /CK-1 $\delta$  Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. *ChemMedChem* **2019**, *14*, 310–314. [CrossRef]
174. Barczuk, J.; Siwecka, N.; Lusa, W.; Rozpędek-Kamińska, W.; Kucharska, E.; Majsterek, I. Targeting NLRP3-Mediated Neuroinflammation in Alzheimer's Disease Treatment. *Int. J. Mol. Sci.* **2022**, *23*, 8979. [CrossRef]
175. Załuski, M.; Łażewska, D.; Jaško, P.; Honkisz-Orzechowska, E.; Kuder, K.J.; Brockmann, A.; Latacz, G.; Zygmunt, M.; Kaleta, M.; Greser, B.A.; et al. Anti-Inflammatory Activities of 8-Benzylaminoxanthines Showing High Adenosine A2A and Dual A1/A2A Receptor Affinity. *Int. J. Mol. Sci.* **2023**, *24*, 13707. [CrossRef] [PubMed]
176. Alghamdi, S.S.; Mustafa, S.M.; Moore Li, B.M. Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189. *Bioorg. Med. Chem.* **2021**, *33*, 116035. [CrossRef] [PubMed]
177. Tung, M.-C.; Fung, K.-M.; Hsu, H.-M.; Tseng, T.-S. Discovery of 8-prenylnaringenin from hop (*Humulus lupulus* L.) as a potent monoacylglycerol lipase inhibitor for treatments of neuroinflammation and Alzheimer's disease. *RSC Adv.* **2021**, *11*, 31062–31072. [CrossRef]
178. Harrison, D.; Bock, M.G.; Doedens, J.R.; Gabel, C.A.; Holloway, M.K.; Lewis, A.; Scanlon, J.; Sharpe, A.; Simpson, I.D.; Smolak, P.; et al. Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors. *ACS Med. Chem. Lett.* **2022**, *13*, 1321–1328. [CrossRef]
179. Behl, T.; Madaan, P.; Sehgal, A.; Singh, S.; Sharma, N.; Bhatia, S.; Al-Harrasi, A.; Chigurupati, S.; Alrashdi, I.; Bungau, S.G. Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target. *Int. J. Mol. Sci.* **2021**, *22*, 10161. [CrossRef]
180. Vaidya, B.; Gupta, P.; Laha, J.K.; Roy, I.; Sharma, S.S. Amelioration of Parkinson's disease by pharmacological inhibition and knockdown of redox sensitive TRPC5 channels: Focus on mitochondrial health. *Life Sci.* **2023**, *328*, 121871. [CrossRef] [PubMed]
181. Sharma, V.K.; Singh, T.G.; Singh, S.; Garg, N.; Dhiman, S. Apoptotic Pathways and Alzheimer's Disease: Probing Therapeutic Potential. *Neurochem. Res.* **2021**, *46*, 3103–3122. [CrossRef]

182. Zhao, D.; Yang, K.; Guo, H.; Zeng, J.; Wang, S.; Xu, H.; Ge, A.; Zeng, L.; Chen, S.; Ge, J. Mechanisms of ferroptosis in Alzheimer's disease and therapeutic effects of natural plant products: A review. *Biomed. Pharmacother.* **2023**, *164*, 114312. [[CrossRef](#)]
183. Malar, D.S.; Thitilertdech, P.; Ruckvongacheep, K.S.; Brimson, S.; Tencomnao, T.; Brimson, J.M. Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders. *CNS Drugs* **2023**, *37*, 399–440. [[CrossRef](#)]
184. Reudhabibadh, R.; Binlath, T.; Chonpathompikunlert, P.; Nonpanya, N.; Prommeenate, P.; Chanvorachote, P.; Hutamekalin, P. Suppressing Cdk5 Activity by Luteolin Inhibits MPP<sup>+</sup>-Induced Apoptotic of Neuroblastoma through Erk/Drp1 and Fak/Akt/GSK3 $\beta$  Pathways. *Molecules* **2021**, *26*, 1307. [[CrossRef](#)]
185. Chen, L.; Huang, Y.; Yu, X.; Lu, J.; Jia, W.; Song, J.; Liu, L.; Wang, Y.; Huang, Y.; Xie, J.; et al. Corynoxine Protects Dopaminergic Neurons Through Inducing Autophagy and Diminishing Neuroinflammation in Rotenone-Induced Animal Models of Parkinson's Disease. *Front. Pharmacol.* **2021**, *12*, 642900. [[CrossRef](#)]
186. Kuleskaya, N.; Bhattacharjee, A.; Holmström, K.M.; Vuorio, P.; Henriques, A.; Callizot, N.; Huttunen, H.J. HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson's disease. *Cell Chem. Biol.* **2024**, *31*, 593–606.e9. [[CrossRef](#)]
187. Ding, X.-s.; Gao, L.; Han, Z.; Eleuteri, S.; Shi, W.; Shen, Y.; Song, Z.-y.; Su, M.; Yang, Q.; Qu, Y.; et al. Ferroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential. *Ageing Res. Rev.* **2023**, *91*, 102077. [[CrossRef](#)]
188. Vietor, J.; Gege, C.; Stiller, T.; Busch, R.; Schallmayer, E.; Kohlhof, H.; Höfner, G.; Pabel, J.; Marschner, J.A.; Merk, D. Development of a Potent Nurr1 Agonist Tool for In Vivo Applications. *J. Med. Chem.* **2023**, *66*, 6391–6402. [[CrossRef](#)]
189. Wang, M.; Wan, C.; He, T.; Han, C.; Zhu, K.; Waddington, J.L.; Zhen, X. Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection. *Neuropharmacology* **2021**, *196*, 108360. [[CrossRef](#)] [[PubMed](#)]
190. Forman, H.J.; Zhang, H. Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy. *Nat. Rev. Drug Discov.* **2021**, *20*, 689–709. [[CrossRef](#)]
191. Hammad, M.; Raftari, M.; Cesário, R.; Salma, R.; Godoy, P.; Emami, S.N.; Haghdoost, S. Roles of Oxidative Stress and Nrf2 Signaling in Pathogenic and Non-Pathogenic Cells: A Possible General Mechanism of Resistance to Therapy. *Antioxidants* **2023**, *12*, 1371. [[CrossRef](#)]
192. Elmazoglu, Z.; Prnova, M.S.; Santamaria, A.; Stefek, M.; Karasu, C. Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose. *Neurotox. Res.* **2021**, *39*, 210–226. [[CrossRef](#)]
193. Choi, J.W.; Kim, S.; Yoo, J.S.; Kim, H.J.; Kim, H.J.; Kim, B.E.; Lee, E.H.; Lee, Y.S.; Park, J.-H.; Park, K.D. Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease. *Eur. J. Med. Chem.* **2021**, *212*, 113103. [[CrossRef](#)]
194. Burns, L.H.; Pei, Z.; Wang, H.-Y. Targeting  $\alpha 7$  nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development. *Drug Dev. Res.* **2023**, *84*, 1085–1095. [[CrossRef](#)] [[PubMed](#)]
195. Nordberg, A.; Ballard, C.; Bullock, R.; Darreh-Shori, T.; Somogyi, M. A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer's Disease. *Prim. Care Companion J. Clin. Psychiatry* **2013**, *15*, 26731. [[CrossRef](#)] [[PubMed](#)]
196. Hardingham, G.E. Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer's Disease? *Cell Metab.* **2020**, *31*, 439–440. [[CrossRef](#)] [[PubMed](#)]
197. Ma, M.; Yang, Y.; Du, G.; Dai, Y.; Zhu, X.; Wang, W.; Xu, H.; Zhang, J.; Zheng, L.; Zou, F.; et al. Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT<sub>2A</sub> receptor antagonists/inverse agonists. *Eur. J. Med. Chem.* **2022**, *234*, 114246. [[CrossRef](#)] [[PubMed](#)]
198. Matthee, C.; Terre'Blanche, G.; Janse van Rensburg, H.D.; Aucamp, J.; Legoabe, L.J. Chalcone-inspired rA1/A2A adenosine receptor ligands: Ring closure as an alternative to a reactive substructure. *Chem. Biol. Drug Des.* **2022**, *99*, 416–437. [[CrossRef](#)] [[PubMed](#)]
199. Rohilla, S.; Bansal, R.; Kachler, S.; Klotz, K.-N. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthenes as potent and selective A<sub>2A</sub> AR ligands with in vivo efficacy against animal model of Parkinson's disease. *Bioorg. Chem.* **2019**, *87*, 601–612. [[CrossRef](#)] [[PubMed](#)]
200. Christie, L.A.; Brice, N.L.; Rowland, A.; Dickson, L.; Anand, R.; Teall, M.; Doyle, K.J.; Narayana, L.; Mitchell, C.; Harvey, J.R.M.; et al. Discovery of CVN417, a Novel Brain-Penetrant  $\alpha 6$ -Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction. *J. Med. Chem.* **2023**, *66*, 11718–11731. [[CrossRef](#)] [[PubMed](#)]
201. de Beer, J.; Petzer, J.P.; Lourens, A.C.U.; Petzer, A. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase. *Mol. Divers.* **2021**, *25*, 753–762. [[CrossRef](#)] [[PubMed](#)]
202. García-Cárceles, J.; Vázquez-Villa, H.; Brea, J.; Ladron de Guevara-Miranda, D.; Cincilla, G.; Sánchez-Martínez, M.; Sánchez-Merino, A.; Algar, S.; Teresa de los Frailes, M.; Roberts, R.S.; et al. 2-(Fluoromethoxy)-4'-(S-methanesulfonylimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson's Disease. *J. Med. Chem.* **2022**, *65*, 12256–12272. [[CrossRef](#)]
203. Sampaio-Dias, I.E.; Reis-Mendes, A.; Costa, V.M.; García-Mera, X.; Brea, J.; Loza, M.I.; Pires-Lima, B.L.; Alcoholado, C.; Algarra, M.; Rodríguez-Borges, J.E. Discovery of New Potent Positive Allosteric Modulators of Dopamine D<sub>2</sub> Receptors: Insights into the Bioisosteric Replacement of Proline to 3-Furoic Acid in the Melanostatin Neuropeptide. *J. Med. Chem.* **2021**, *64*, 6209–6220. [[CrossRef](#)]

204. Tolentino, K.T.; Mashinson, V.; Vadukoot, A.K.; Hopkins, C.R. Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists. *Bioorg. Med. Chem. Lett.* **2022**, *61*, 128615. [[CrossRef](#)] [[PubMed](#)]
205. Sun, H.; Monenschein, H.; Schiffer, H.H.; Reichard, H.A.; Kikuchi, S.; Hopkins, M.; Macklin, T.K.; Hitchcock, S.; Adams, M.; Green, J.; et al. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. *J. Med. Chem.* **2021**, *64*, 9875–9890. [[CrossRef](#)] [[PubMed](#)]
206. Rehuman, N.A.; Oh, J.M.; Abdelgawad, M.A.; Beshr, E.A.M.; Abourehab, M.A.S.; Gambacorta, N.; Nicolotti, O.; Jat, R.K.; Kim, H.; Mathew, B. Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors. *Pharmaceutics* **2022**, *15*, 1152. [[CrossRef](#)] [[PubMed](#)]
207. Kent, C.N.; Fulton, M.G.; Stillwell, K.J.; Dickerson, J.W.; Loch, M.T.; Rodriguez, A.L.; Blobaum, A.L.; Boutaud, O.; Rook, J.L.; Niswender, C.M.; et al. Discovery and optimization of a novel CNS penetrant series of mGlu4 PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model. *Bioorg. Med. Chem. Lett.* **2021**, *37*, 127838. [[CrossRef](#)] [[PubMed](#)]
208. Tang, L.; Huang, C.; Zhong, J.; He, J.; Guo, J.; Liu, M.; Xu, J.-P.; Wang, H.-T.; Zhou, Z.-Z. Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. *Eur. J. Med. Chem.* **2019**, *168*, 221–231. [[CrossRef](#)] [[PubMed](#)]
209. Learmonth, D.A.; Palma, P.N.; Vieira-Coelho, M.A.; Soares-da-Silva, P. Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. *J. Med. Chem.* **2004**, *47*, 6207–6217. [[CrossRef](#)] [[PubMed](#)]
210. Pinheiro, S.D.; Serrao, M.P.; Silva, T.; Borges, F.; Soares-da-Silva, P. Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors. *Eur. J. Pharmacol.* **2019**, *847*, 53–60. [[CrossRef](#)]
211. Vianello, R.; Domene, C.; Mavri, J. The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes. *Front. Neurosci.* **2016**, *10*, 327. [[CrossRef](#)] [[PubMed](#)]
212. Fabbri, M.; Ferreira, J.J.; Lees, A.; Stocchi, F.; Poewe, W.; Tolosa, E.; Rascol, O. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. *Mov. Disord.* **2018**, *33*, 1528–1539. [[CrossRef](#)]
213. Almeida, L.; Rocha, J.F.; Falcao, A.; Palma, P.N.; Loureiro, A.I.; Pinto, R.; Bonifacio, M.J.; Wright, L.C.; Nunes, T.; Soares-da-Silva, P. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: Prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. *Clin. Pharmacokinet.* **2013**, *52*, 139–151. [[CrossRef](#)]
214. Lees, A.J.; Ferreira, J.; Rascol, O.; Poewe, W.; Rocha, J.F.; McCrory, M.; Soares-da-Silva, P. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. *JAMA Neurol.* **2017**, *74*, 197–206. [[CrossRef](#)] [[PubMed](#)]
215. Parashos, S.A.; Wielinski, C.L.; Kern, J.A. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. *Clin. Neuropharmacol.* **2004**, *27*, 119–123. [[CrossRef](#)] [[PubMed](#)]
216. Käenmäki, M.; Tammimäki, A.; Garcia-Horsman, J.A.; Myöhänen, T.; Schendzielorz, N.; Karayiorgou, M.; Gogos, J.A.; Männistö, P.T. Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: A pharmacokinetic study in two types of Comt gene modified mice. *Br. J. Pharmacol.* **2009**, *158*, 1884–1894. [[CrossRef](#)] [[PubMed](#)]
217. Jellinger, K.A. Basic mechanisms of neurodegeneration: A critical update. *J. Cell. Mol. Med.* **2010**, *14*, 457–487. [[CrossRef](#)] [[PubMed](#)]
218. Rogawski, M.A.; Wenk, G.L. The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease. *CNS Drug Rev.* **2003**, *9*, 275–308. [[CrossRef](#)] [[PubMed](#)]
219. Wenk, G.L.; Parsons, C.G.; Danysz, W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: Focus on memantine. *Behav. Pharmacol.* **2006**, *17*, 411–424. [[CrossRef](#)] [[PubMed](#)]
220. Ong, W.-Y.; Tanaka, K.; Dawe, G.S.; Ittner, L.; Farooqui, A.A. Slow Excitotoxicity in Alzheimer's Disease. *J. Alzheimers Dis.* **2013**, *35*, 643–668. [[CrossRef](#)] [[PubMed](#)]
221. Parsons, C.G.; Danysz, W.; Dekundy, A.; Pulte, I. Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease. *Neurotox. Res.* **2013**, *24*, 358–369. [[CrossRef](#)] [[PubMed](#)]
222. Tariot, P.N.; Farlow, M.R.; Grossberg, G.T.; Graham, S.M.; McDonald, S.; Gergel, I.; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. *JAMA* **2004**, *291*, 317–324. [[CrossRef](#)]
223. Lopez, O.L.; Becker, J.T.; Wahed, A.S.; Saxton, J.; Sweet, R.A.; Wolk, D.A.; Klunk, W.; DeKosky, S.T. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. *J. Neurol. Neurosurg. Ps.* **2009**, *80*, 600. [[CrossRef](#)]
224. Atri, A.; Molinuevo, J.L.; Lemming, O.; Wirth, Y.; Pulte, I.; Wilkinson, D. Memantine in patients with Alzheimer's disease receiving donepezil: New analyses of efficacy and safety for combination therapy. *Alzheimer's Res. Ther.* **2013**, *5*, 6. [[CrossRef](#)] [[PubMed](#)]
225. Greig, S.L. Memantine ER/Donepezil: A Review in Alzheimer's Disease. *CNS Drugs* **2015**, *29*, 963–970. [[CrossRef](#)] [[PubMed](#)]
226. Rösler, M.; Bayer, T.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stähelin, H.B.; Hartman, R.; Gharabawi, M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. *BMJ* **1999**, *318*, 633–640. [[CrossRef](#)] [[PubMed](#)]

227. Raskind, M.A.; Peskind, E.R.; Wessel, T.; Yuan, W. Galantamine in AD. *Neurology* **2000**, *54*, 2261–2268. [[CrossRef](#)] [[PubMed](#)]
228. Birks, J.; Harvey, R.J. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst.* **2003**, CD001190.
229. Parsons, C.G.; Stöffler, A.; Danysz, W. Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—Too little activation is bad, too much is even worse. *Neuropharmacology* **2007**, *53*, 699–723. [[CrossRef](#)] [[PubMed](#)]
230. Hansen, R.A.; Gartlehner, G.; Webb, A.P.; Morgan, L.C.; Moore, C.G.; Jonas, D.E. Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. *Clin. Interv. Aging.* **2008**, *3*, 211–225. [[PubMed](#)]
231. Di, L.; Kerns, E.H. *Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs*; Wiley: Hoboken, NJ, USA, 2015.
232. Domínguez, A.; Álvarez, A.; Hilario, E.; Suarez-Merino, B.; Goñi-de-Cerio, F. Central nervous system diseases and the role of the blood-brain barrier in their treatment. *Neurosci. Discov.* **2013**, *1*, 3. [[CrossRef](#)]
233. Begley, D.J.; Brightman, M.W. Structural and functional aspects of the blood-brain barrier. In *Peptide Transport and Delivery into the Central Nervous System*; Prokai, L., Prokai-Tatrai, K., Eds.; Birkhäuser: Basel, Switzerland, 2003; pp. 39–78.
234. Pardridge, W.M. Molecular biology of the blood-brain barrier. *Mol. Biotechnol.* **2005**, *30*, 57–69. [[CrossRef](#)]
235. Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood–brain barrier. *Adv. Drug Deliv. Rev.* **2012**, *64*, 640–665. [[CrossRef](#)]
236. Selmaj, K. Pathophysiology of the blood-brain barrier. In *Immunoneurology*; Chofflon, M., Steinman, L., Eds.; Springer: Berlin/Heidelberg, Germany, 1996; pp. 175–191.
237. Rankovic, Z. CNS drug design: Balancing physicochemical properties for optimal brain exposure. *J. Med. Chem.* **2015**, *58*, 2584–2608. [[CrossRef](#)] [[PubMed](#)]
238. Deeken, J.F.; Löscher, W. The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses. *Clin. Cancer Res.* **2007**, *13*, 1663–1674. [[CrossRef](#)] [[PubMed](#)]
239. Kasinathan, N.; Jagani, H.V.; Alex, A.T.; Volety, S.M.; Rao, J.V. Strategies for drug delivery to the central nervous system by systemic route. *Drug Deliv.* **2015**, *22*, 243–257. [[CrossRef](#)] [[PubMed](#)]
240. Jones, P.M.; George, A.M. The ABC transporter structure and mechanism: Perspectives on recent research. *Cell. Mol. Life Sci.* **2004**, *61*, 682–699. [[CrossRef](#)]
241. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. *Adv. Drug Deliv. Rev.* **2003**, *55*, 3–29. [[CrossRef](#)] [[PubMed](#)]
242. Yildirim-Balatan, C.; Fenyi, A.; Besnault, P.; Gomez, L.; Sepulveda-Diaz, J.E.; Michel, P.P.; Melki, R.; Hunot, S. Parkinson's disease-derived  $\alpha$ -synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype. *J. Neuroinflamm.* **2024**, *21*, 54. [[CrossRef](#)] [[PubMed](#)]
243. Bingham, M.; Rankovic, Z. CHAPTER 18 Medicinal Chemistry Challenges in CNS Drug Discovery. In *Drug Discovery for Psychiatric Disorders*; The Royal Society of Chemistry: London, UK, 2012; pp. 465–509.
244. Pajouhesh, H.; Lenz, G.R. Medicinal Chemical Properties of Successful Central Nervous System Drugs. *NeuroRx* **2005**, *2*, 541–553. [[CrossRef](#)] [[PubMed](#)]
245. Kiss, L.E.; Soares-da-Silva, P. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. *J. Med. Chem.* **2014**, *57*, 8692–8717. [[CrossRef](#)] [[PubMed](#)]
246. Strydom, B.; Bergh, J.J.; Petzer, J.P. 8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase. *Eur. J. Med. Chem.* **2011**, *46*, 3474–3485. [[CrossRef](#)]
247. Hitchcock, S.A.; Pennington, L.D. Structure–Brain Exposure Relationships. *J. Med. Chem.* **2006**, *49*, 7559–7583. [[CrossRef](#)]
248. Wager, T.T.; Hou, X.; Verhoest, P.R.; Villalobos, A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. *ACS Chem. Neurosci.* **2010**, *1*, 435–449. [[CrossRef](#)] [[PubMed](#)]
249. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. *J. Pharmacol. Tox. Met.* **2000**, *44*, 235–249. [[CrossRef](#)] [[PubMed](#)]
250. Abraham, M.H.; Ibrahim, A.; Acree, W.E. Air to brain, blood to brain and plasma to brain distribution of volatile organic compounds: Linear free energy analyses. *Eur. J. Med. Chem.* **2006**, *41*, 494–502. [[CrossRef](#)] [[PubMed](#)]
251. Wisniewski, T.; Goñi, F. Immunotherapy for Alzheimer's disease. *Biochem. Pharmacol.* **2014**, *88*, 499–507. [[CrossRef](#)]
252. Panza, F.; Solfrizzi, V.; Imbimbo, B.P.; Tortelli, R.; Santamato, A.; Logroscino, G. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward. *Expert Rev. Clin. Immunol.* **2014**, *10*, 405–419. [[CrossRef](#)] [[PubMed](#)]
253. Anand, R.; Gill, K.D.; Mahdi, A.A. Therapeutics of Alzheimer's disease: Past, present and future. *Neuropharmacology* **2014**, *76*, 27–50. [[CrossRef](#)]
254. Tayeb, H.O.; Murray, E.D.; Price, B.H.; Tarazi, F.I. Bapineuzumab and solanezumab for Alzheimer's disease: Is the 'amyloid cascade hypothesis' still alive? *Expert Opin. Biol. Ther.* **2013**, *13*, 1075–1084. [[CrossRef](#)] [[PubMed](#)]
255. Jia, Q.; Deng, Y.; Qing, H. Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond  $\beta$ -Amyloid: Insights from Clinical Trials. *Biomed. Res. Int.* **2014**, *2014*, 837157. [[CrossRef](#)] [[PubMed](#)]
256. Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody aducanumab reduces A $\beta$  plaques in Alzheimer's disease. *Nature* **2016**, *537*, 50. [[CrossRef](#)]

257. Hardy, J.; De Strooper, B. Alzheimer's Disease: Where next for anti-amyloid therapies? *Brain* **2017**, *140*, 853–855. [CrossRef]
258. Ghosh, A.K.; Osswald, H.L. BACE1 (small beta)-secretase inhibitors for the treatment of Alzheimer's disease. *Chem. Soc. Rev.* **2014**, *43*, 6765–6813. [CrossRef] [PubMed]
259. Murphy, M.P. Targeting lipophilic cations to mitochondria. *Biochim. Biophys. Acta* **2008**, *1777*, 1028–1031. Available online: <https://www.sciencedirect.com/science/article/pii/S0005272808000790?via=ihub> (accessed on 3 April 2024). [CrossRef] [PubMed]
260. Abu-Gosh, S.E.; Kolvazon, N.; Tirosh, B.; Ringel, I.; Yavin, E. Multiple triphenylphosphonium cations shuttle a hydrophilic peptide into mitochondria. *Mol. Pharm* **2009**, *6*, 1138–1144. [CrossRef] [PubMed]
261. Grüniger, F. Invited review: Drug development for tauopathies. *Neuropath. Appl. Neuro.* **2015**, *41*, 81–96. [CrossRef] [PubMed]
262. Teixeira, J.; Oliveira, C.; Amorim, R.; Cagide, F.; Garrido, J.; Ribeiro, J.A.; Pereira, C.M.; Silva, A.F.; Andrade, P.B.; Oliveira, P.J.; et al. Development of hydroxybenzoic-based platforms as a solution to deliver dietary antioxidants to mitochondria. *Sci. Rep.* **2017**, *7*, 6842. [CrossRef]
263. Teixeira, J.; Cagide, F.; Benfeito, S.; Soares, P.; Garrido, J.; Baldeiras, I.; Ribeiro, J.A.; Pereira, C.M.; Silva, A.F.; Andrade, P.B.; et al. Development of a Mitochondriotropic Antioxidant Based on Caffeic Acid: Proof of Concept on Cellular and Mitochondrial Oxidative Stress Models. *J. Med. Chem.* **2017**, *60*, 7084–7098. [CrossRef]
264. Benfeito, S.; Oliveira, C.; Fernandes, C.; Cagide, F.; Teixeira, J.; Amorim, R.; Garrido, J.; Martins, C.; Sarmiento, B.; Silva, R.; et al. Fine-tuning the neuroprotective and blood-brain barrier permeability profile of multi-target agents designed to prevent progressive mitochondrial dysfunction. *Eur. J. Med. Chem.* **2019**, *167*, 525–545. [CrossRef]
265. Deus, C.M.; Pereira, S.P.; Cunha-Oliveira, T.; Teixeira, J.; Simões, R.F.; Cagide, F.; Benfeito, S.; Borges, F.; Raimundo, N.; Oliveira, P.J. A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patients. *Redox Biol.* **2021**, *45*, 102037. [CrossRef]
266. Benfeito, S.; Fernandes, C.; Chavarria, D.; Barreiro, S.; Cagide, F.; Sequeira, L.; Teixeira, J.; Silva, R.; Remião, F.; Oliveira, P.J.; et al. Modulating Cytotoxicity with Lego-like Chemistry: Upgrading Mitochondriotropic Antioxidants with Prototypical Cationic Carrier Bricks. *J. Med. Chem.* **2023**, *66*, 1835–1851. [CrossRef]
267. Chang, C.-P.; Wu, K.-C.; Lin, C.-Y.; Chern, Y. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. *J. Biomed. Sci.* **2021**, *28*, 70. [CrossRef]
268. Garcia-Gil, M.; Camici, M.; Allegrini, S.; Pesi, R.; Tozzi, M.G. Metabolic Aspects of Adenosine Functions in the Brain. *Front. Pharmacol.* **2021**, *12*, 672182. [CrossRef] [PubMed]
269. Mazziotta, C.; Rotondo, J.C.; Lanzillotti, C.; Campione, G.; Martini, F.; Tognon, M. Cancer biology and molecular genetics of A3 adenosine receptor. *Oncogene* **2022**, *41*, 301–308. [CrossRef] [PubMed]
270. Comeo, E.; Kindon, N.D.; Soave, M.; Stoddart, L.A.; Kilpatrick, L.E.; Scammells, P.J.; Hill, S.J.; Kellam, B. Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A2A Receptor. *J. Med. Chem.* **2020**, *63*, 2656–2672. [CrossRef] [PubMed]
271. Candito, D.A.; Simov, V.; Gulati, A.; Kattar, S.; Chau, R.W.; Lapointe, B.T.; Methot, J.L.; DeMong, D.E.; Graham, T.H.; Kurukulasuriya, R.; et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. *J. Med. Chem.* **2022**, *65*, 16801–16817. [CrossRef] [PubMed]
272. Hagenow, S.; Affini, A.; Pioli, E.Y.; Hinz, S.; Zhao, Y.; Porras, G.; Namasivayam, V.; Müller, C.E.; Lin, J.-S.; Bezdard, E.; et al. Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson's Disease. *J. Med. Chem.* **2021**, *64*, 8246–8262. [CrossRef] [PubMed]
273. Janse van Rensburg, H.D.; Legoabe, L.J.; Terre'Blanche, G.; Aucamp, J. Synthesis and evaluation of methoxy substituted 2-benzoyl-1-benzofuran derivatives as lead compounds for the development adenosine A1 and/or A2A receptor antagonists. *Bioorg. Chem.* **2020**, *94*, 103459. [CrossRef]
274. Basu, S.; Barawkar, D.A.; Thorat, S.; Shejul, Y.D.; Patel, M.; Naykodi, M.; Jain, V.; Salve, Y.; Prasad, V.; Chaudhary, S.; et al. Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. *J. Med. Chem.* **2017**, *60*, 681–694. [CrossRef] [PubMed]
275. Prasad, K.; de Vries, E.F.J.; van der Meiden, E.; Moraga-Amaro, R.; Vazquez-Matias, D.A.; Barazzuol, L.; Dierckx, R.A.J.O.; van Waarde, A. Effects of the adenosine A2A receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease. *Neuropharmacology* **2024**, *247*, 109862. [CrossRef]
276. Cervetto, C.; Maura, G.; Guidolin, D.; Amato, S.; Ceccoli, C.; Agnati, L.F.; Marcoli, M. Striatal astrocytic A2A-D2 receptor-receptor interactions and their role in neuropsychiatric disorders. *Neuropharmacology* **2023**, *237*, 109636. [CrossRef]
277. Maeda, T.; Kimura, T.; Sugiyama, K.; Yamada, K.; Hiraiwa, R.; Nishi, M.; Hattori, N.; Abe, T.; Deguchi, K.; Fujimoto, K.; et al. Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease. *Park. Relat. Disord.* **2023**, *117*, 105907. [CrossRef]
278. Orr, A.G.; Hsiao, E.C.; Wang, M.M.; Ho, K.; Kim, D.H.; Wang, X.; Guo, W.; Kang, J.; Yu, G.-Q.; Adame, A.; et al. Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. *Nat. Neurosci.* **2015**, *18*, 423–434. [CrossRef] [PubMed]
279. Viana da Silva, S.; Haberl, M.G.; Zhang, P.; Bethge, P.; Lemos, C.; Gonçalves, N.; Gorlewicz, A.; Malezieux, M.; Gonçalves, F.Q.; Grosjean, N.; et al. Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors. *Nat. Commun.* **2016**, *7*, 11915. [CrossRef] [PubMed]

280. Li, P.; Rial, D.; Canas, P.M.; Yoo, J.H.; Li, W.; Zhou, X.; Wang, Y.; van Westen, G.J.P.; Payen, M.P.; Augusto, E.; et al. Optogenetic activation of intracellular adenosine A2A receptor signaling in the hippocampus is sufficient to trigger CREB phosphorylation and impair memory. *Mol. Psychiatry* **2015**, *20*, 1339–1349. [[CrossRef](#)] [[PubMed](#)]
281. Gonçalves, F.Q.; Lopes, J.P.; Silva, H.B.; Lemos, C.; Silva, A.C.; Gonçalves, N.; Tomé, Â.R.; Ferreira, S.G.; Canas, P.M.; Rial, D.; et al. Synaptic and memory dysfunction in a  $\beta$ -amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine. *Neurobiol. Dis.* **2019**, *132*, 104570. [[CrossRef](#)] [[PubMed](#)]
282. Ji, Q.; Yang, Y.; Xiong, Y.; Zhang, Y.-J.; Jiang, J.; Zhou, L.-P.; Du, X.-H.; Wang, C.-X.; Zhu, Z.-R. Blockade of adenosine A2A receptors reverses early spatial memory defects in the APP/PS1 mouse model of Alzheimer's disease by promoting synaptic plasticity of adult-born granule cells. *Alzheimer Res. Ther.* **2023**, *15*, 187. [[CrossRef](#)] [[PubMed](#)]
283. Saini, A.; Patel, R.; Gaba, S.; Singh, G.; Gupta, G.D.; Monga, V. Adenosine receptor antagonists: Recent advances and therapeutic perspective. *Eur. J. Med. Chem.* **2022**, *227*, 113907. [[CrossRef](#)] [[PubMed](#)]
284. Vincenzi, F.; Pasquini, S.; Contri, C.; Cappello, M.; Nigro, M.; Travagli, A.; Merighi, S.; Gessi, S.; Borea, P.A.; Varani, K. Pharmacology of Adenosine Receptors: Recent Advancements. *Biomolecules* **2023**, *13*, 1387. [[CrossRef](#)] [[PubMed](#)]
285. Chen, J.-F.; Cunha, R.A. The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. *Purinergic Signal.* **2020**, *16*, 167–174. [[CrossRef](#)] [[PubMed](#)]
286. Hauser, R.A.; Olanow, C.W.; Kieburtz, K.D.; Pourcher, E.; Docu-Axelerad, A.; Lew, M.; Kozyolkin, O.; Neale, A.; Resburg, C.; Meya, U.; et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: A phase 2b, double-blind, randomised trial. *Lancet Neurol.* **2014**, *13*, 767–776. [[CrossRef](#)] [[PubMed](#)]
287. LeWitt, P.A.; Aradi, S.D.; Hauser, R.A.; Rascol, O. The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. *Park. Relat. Disord.* **2020**, *80*, S54–S63. [[CrossRef](#)]
288. Yutaro, O.; Michihiko, S.; Hidetsugu, A.; Tomoyuki, K.; Mayumi, S.; Hikaru, M.; Mai, Y.; Chiyo, S.; So, I.; Jun-ichi, S.; et al. In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A<sub>2A</sub> Receptor Antagonist/Inverse Agonist. *Mol. Pharmacol.* **2023**, *103*, 311.
289. Ntetsika, T.; Paphoma, P.-E.; Markaki, I. Novel targeted therapies for Parkinson's disease. *Mol. Med.* **2021**, *27*, 1–20. [[CrossRef](#)] [[PubMed](#)]
290. Hargreaves, R.J.; Hoppin, J.; Seigny, J.; Patel, S.; Chiao, P.; Klimas, M.; Verma, A. Optimizing central nervous system drug development using molecular imaging. *Clin. Pharmacol. Ther.* **2015**, *98*, 47–60. [[CrossRef](#)] [[PubMed](#)]
291. Savelieff, M.G.; Nam, G.; Kang, J.; Lee, H.J.; Lee, M.; Lim, M.H. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. *Chem. Rev.* **2019**, *119*, 1221–1322. [[CrossRef](#)] [[PubMed](#)]
292. Prati, F.; Cavalli, A.; Bolognesi, M.L. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease. *Molecules* **2016**, *21*, 466. [[CrossRef](#)]
293. Proschak, E.; Stark, H.; Merk, D. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. *J. Med. Chem.* **2018**, *62*, 420–444. [[CrossRef](#)]
294. Ramsay, R.R.; Popovic-Nikolic, M.R.; Nikolic, K.; Uliassi, E.; Bolognesi, M.L. A perspective on multi-target drug discovery and design for complex diseases. *Clin. Transl. Med.* **2018**, *7*, 3. [[CrossRef](#)] [[PubMed](#)]
295. Grosso, C.; Silva, A.; Delerue-Matos, C.; Barroso, M.F. Single and Multitarget Systems for Drug Delivery and Detection: Up-to-Date Strategies for Brain Disorders. *Pharmaceutics* **2023**, *16*, 1721. [[CrossRef](#)]
296. Bolognesi, M.L. Polypharmacology in a single drug: Multitarget drugs. *Curr. Med. Chem.* **2013**, *20*, 1639–1645. [[CrossRef](#)]
297. Mesiti, F.; Chavarria, D.; Gaspar, A.; Alcaro, S.; Borges, F. The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease. *Eur. J. Med. Chem.* **2019**, *181*, 111572. [[CrossRef](#)]
298. Pathak, C.; Kabra, U.D. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease. *Bioorg. Chem.* **2024**, *144*, 107152. [[CrossRef](#)] [[PubMed](#)]
299. Tong, Y.; Zhu, W.; Chen, J.; Zhang, W.; Xu, F.; Pang, J. Targeted Degradation of Alpha-Synuclein by Autophagosome-Anchoring Chimera Peptides. *J. Med. Chem.* **2023**, *66*, 12614–12628. [[CrossRef](#)] [[PubMed](#)]
300. Zhu, W.; Zhang, W.; Chen, J.; Tong, Y.; Xu, F.; Pang, J. Discovery of Effective Dual PROTAC Degradable for Neurodegenerative Disease-Associated Aggregates. *J. Med. Chem.* **2024**, *67*, 3448–3466. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.